<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Rev Mol Cell Biol</journal-id><journal-id journal-id-type="iso-abbrev">Nat Rev Mol Cell Biol</journal-id><journal-id journal-id-type="pmc-domain-id">3814</journal-id><journal-id journal-id-type="pmc-domain">phenaturepg</journal-id><journal-title-group><journal-title>Nature Reviews. Molecular Cell Biology</journal-title></journal-title-group><issn pub-type="ppub">1471-0072</issn><issn pub-type="epub">1471-0080</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer Nature - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8491763</article-id><article-id pub-id-type="pmcid-ver">PMC8491763.1</article-id><article-id pub-id-type="pmcaid">8491763</article-id><article-id pub-id-type="pmcaiid">8491763</article-id><article-id pub-id-type="pmid">34611326</article-id><article-id pub-id-type="doi">10.1038/s41580-021-00418-x</article-id><article-id pub-id-type="publisher-id">418</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Mechanisms of SARS-CoV-2 entry into cells</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0686-9423</contrib-id><name name-style="western"><surname>Jackson</surname><given-names initials="CB">Cody B.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2990-5319</contrib-id><name name-style="western"><surname>Farzan</surname><given-names initials="M">Michael</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8625-1657</contrib-id><name name-style="western"><surname>Chen</surname><given-names initials="B">Bing</given-names></name><address><email>bchen@crystal.harvard.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4538-7176</contrib-id><name name-style="western"><surname>Choe</surname><given-names initials="H">Hyeryun</given-names></name><address><email>hchoe@scripps.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.214007.0</institution-id><institution-id institution-id-type="ISNI">0000000122199231</institution-id><institution>Department of Immunology and Microbiology, </institution><institution>Scripps Research, </institution></institution-wrap>Jupiter, FL USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution>Division of Molecular Medicine, </institution><institution>Boston Children&#8217;s Hospital, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Department of Pediatrics, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.255951.f</institution-id><institution>Present Address: Charles E. Schmidt College of Medicine, </institution><institution>Florida Atlantic University, </institution></institution-wrap>Boca Raton, FL USA </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="ppub"><year>2022</year></pub-date><volume>23</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">391274</issue-id><fpage>3</fpage><lpage>20</lpage><history><date date-type="accepted"><day>26</day><month>8</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>10</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>06</day><month>10</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-27 10:25:44.963"><day>27</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply. 2021</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41580_2021_Article_418.pdf"/><abstract id="Abs1"><p id="Par1">The unprecedented public health and economic impact of the COVID-19 pandemic caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been met with an equally unprecedented scientific response. Much of this response has focused, appropriately, on the mechanisms of SARS-CoV-2 entry into host cells, and in particular the binding of the spike (S) protein to its receptor, angiotensin-converting enzyme 2 (ACE2), and subsequent membrane fusion. This Review provides the structural and cellular foundations for understanding the multistep SARS-CoV-2 entry process, including S protein synthesis, S protein structure, conformational transitions necessary for association of the S protein with ACE2, engagement of the receptor-binding domain of the S protein with ACE2, proteolytic activation of the S protein, endocytosis and membrane fusion. We define the roles of furin-like proteases, transmembrane protease, serine 2 (TMPRSS2) and cathepsin L in these processes, and delineate the features of ACE2 orthologues in reservoir animal species and S protein adaptations that facilitate efficient human transmission. We also examine the utility of vaccines, antibodies and other potential therapeutics targeting SARS-CoV-2 entry mechanisms. Finally, we present key outstanding questions associated with this critical process.</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par2">Entry of SARS-CoV-2 into host cells is mediated by the interaction between the viral spike protein and its receptor angiotensin-converting enzyme 2, followed by virus&#8211;cell membrane fusion. Worldwide research efforts have provided a detailed understanding of this process at the structural and cellular levels, enabling successful vaccine development for a rapid response to the COVID-19 pandemic.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>SARS-CoV-2</kwd><kwd>Membrane trafficking</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2022</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19, which escalated into a global pandemic in 2020. SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus of the genus Betacoronavirus<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. In addition to SARS-CoV, which was responsible for the 2002&#8211;2004 SARS epidemic and which shares 79% nucleotide sequence identity with SARS-CoV-2 (ref.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>), the genus also includes human coronavirus (HCoV)-OC43, HCoV-HKU1 and Middle East respiratory syndrome coronavirus (MERS-CoV). SARS-CoV-2 relies on its obligate receptor, <xref rid="Glos1" ref-type="list">angiotensin-converting enzyme 2</xref> (ACE2), to enter cells<sup><xref ref-type="bibr" rid="CR2">2</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref></sup>; ACE2 was originally identified in 2003 as the receptor for SARS-CoV<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. ACE2 is also the receptor for alphacoronavirus HCoV-NL63, which, together with another alphacoronavirus, HCoV-229E, and betacoronaviruses HCoV-OC43 and HCoV-HKU1, is a known causative agent of mild upper respiratory tract infections<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p><p id="Par4">The coronavirus virion is made up of the nucleocapsid (N), membrane (M), envelope (E) and spike (S) proteins, which are structural proteins (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The entry steps of the viral particles &#8212; encompassing attachment to the host cell membrane and fusion &#8212; are mediated by the&#160;S glycoprotein. S protein is assembled as a homotrimer and is inserted in multiple copies into the membrane of the virion giving it its crown-like appearance. Entry&#160;glycoproteins of many viruses, including HIV-1, Ebola virus and avian influenza viruses, are cleaved into two subunits &#8212; extracellular and transmembrane &#8212; in the infected cells (that is, the cleavage occurs before release of the virus from the cell that produces it). Similarly, the S protein of some coronaviruses is cleaved into S1 and S2 subunits during their biosynthesis in the infected cells, while the S protein of other coronaviruses is cleaved only when they reach the next target cell. SARS-CoV-2, like MERS-CoV, belongs to the first category: its S protein is cleaved by <xref rid="Glos2" ref-type="list">proprotein convertases</xref> such as <xref rid="Glos3" ref-type="list">furin</xref> in the virus-producer cells<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup> (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Therefore, the S protein on the mature virion consists of two non-covalently associated subunits: the S1 subunit binds ACE2 and&#160;the S2 subunit anchors the S&#160;protein to the membrane. The S2 subunit also includes a <xref rid="Glos4" ref-type="list">fusion peptide</xref> and other machinery necessary to mediate membrane fusion upon infection of a new cell<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Coronavirus structure and maturation.</title><p>Infection by a coronavirus induces in the perinuclear area the formation of new membranous structures of various sizes and shapes, which as a whole are referred to as &#8216;replication organelles&#8217;<sup><xref ref-type="bibr" rid="CR225">225</xref>&#8211;<xref ref-type="bibr" rid="CR229">229</xref></sup>. These structures &#8212; observed by electron microscopy in cells infected with mouse hepatitis virus, severe acute respiratory syndrome coronavirus or Middle East respiratory syndrome coronavirus and typically surrounded by double membranes &#8212; likely originate from the endoplasmic reticulum (ER) and house viral replication complexes, sequestering them from cellular innate immune molecules. Viral structural proteins and genomic RNA synthesized at the replication site are then translocated through an unknown mechanism to the ER&#8211;Golgi intermediate compartment (ERGIC), where virus assembly and budding occur<sup><xref ref-type="bibr" rid="CR228">228</xref>,<xref ref-type="bibr" rid="CR230">230</xref></sup>. Only four viral proteins &#8212; the spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins &#8212; are incorporated into the virion. While the N protein bound to the viral genomic RNA is packed inside the virion, the structural proteins S, E and M are incorporated in the virion membrane. The S protein, assembled as a trimer, giving the&#160;appearance of a crown (corona), mediates major entry steps, including receptor binding and membrane fusion. During biosynthesis and maturation in the infected cell, the S protein is cleaved by furin or furin-like proprotein convertase in the Golgi apparatus into the S1 and S2 subunits, which remain associated<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>. The S protein on the virus therefore consists of two non-covalently associated subunits with different functions: in the new target cell, the S1 subunit binds the receptor and the S2 subunit anchors the S protein to the virion membrane and mediates membrane fusion. The E and M proteins contribute to virus assembly and budding through the interactions with other viral proteins<sup><xref ref-type="bibr" rid="CR231">231</xref>,<xref ref-type="bibr" rid="CR232">232</xref></sup>. Assembled viruses bud into the ERGIC lumen and reach the plasma membrane via the secretory pathway, where they are released into the extracellular space after virus-containing vesicles fuse with the plasma membrane. FP, fusion peptide.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e371" position="float" orientation="portrait" xlink:href="41580_2021_418_Fig1_HTML.jpg"/></fig></p><p id="Par5">Receptor engagement by viral entry glycoproteins, typically with other triggers, induces dramatic conformational changes in both subunits that bring the viral and cellular membranes together, ultimately creating a fusion pore that allows the viral genome to reach the cell cytoplasm. For SARS-CoV-2, one such trigger is the cleavage of an additional site internal to the S2 subunit, termed the &#8216;S2&#8242; site&#8217;. ACE2 engagement by the virus exposes the S2&#8242; site. S2&#8242; site cleavage&#160;&#8212; by&#160;<xref rid="Glos5" ref-type="list">transmembrane protease, serine 2</xref> (TMPRSS2)<sup><xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref></sup> at the cell surface or by <xref rid="Glos6" ref-type="list">cathepsin L</xref><sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup> in the endosomal compartment following ACE2-mediated endocytosis<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>&#160;&#8212; releases the fusion peptide, initiating fusion pore formation (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Because the viral genome must access the cytoplasm and because it can do so only as this pore expands and the viral and cell membranes are seamlessly combined, every step of this process is important.</p><p id="Par6">This Review provides the structural and cell biological foundations for understanding the multistep SARS-CoV-2 entry process. Much of the SARS-CoV-2 entry process was informed by prior studies of SARS-CoV, which shares a similar entry process, and combined interpretation of studies focused on infectious SARS-CoV-2, <xref rid="Glos7" ref-type="list">pseudoviruses</xref>, <xref rid="Glos8" ref-type="list">virus-like particles</xref> and structural analyses of the S protein. We also discuss S protein evolution and mutation supporting adaptation to the human host and provide an overview of current vaccine approaches and therapeutic strategies targeting SARS-CoV-2 entry mechanisms.</p></sec><sec id="Sec2"><title>Coronavirus S protein</title><p id="Par7">The monomeric S protein of SARS-CoV-2 is a <xref rid="Glos9" ref-type="list">type I membrane protein</xref> with 66 <italic toggle="yes">N</italic>-linked glycans per S protein trimer<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> and belongs to the so-called class I viral fusion proteins exemplified by the influenza virus haemagglutinin protein. Accordingly, S proteins of coronaviruses and haemagglutinin share structural organization and conformational transition that promotes membrane fusion<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>.</p><sec id="Sec3"><title>Overall structure of S trimer</title><p id="Par8">Structural biology of the SARS-CoV-2 S protein has advanced very rapidly since the initial outbreak of COVID-19. Structures of S protein fragments (Fig.&#160;<xref rid="Fig2" ref-type="fig">2a</xref>) derived from the Wuhan-Hu-1 strain, including the ectodomain stabilized in its prefusion conformation<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>, receptor binding domain (RBD)&#8211;ACE2 complexes<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup> and segments of the S2 subunit in the postfusion conformation<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, were determined by either cryo-electron microscopy (cryo-EM) or X-ray crystallography. They were followed by structures of detergent-solubilized, full-length S proteins<sup><xref ref-type="bibr" rid="CR25">25</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref></sup> (Fig.&#160;<xref rid="Fig2" ref-type="fig">2b</xref>&#8211;<xref rid="Fig2" ref-type="fig">d</xref>), as well as those of the membrane-bound, intact S proteins on the surface of the virion, which were obtained by cryo-electron tomography using chemically inactivated SARS-CoV-2 preparations of both the Wuhan-Hu-1 strain and a B.1 variant carrying the D614G mutation<sup><xref ref-type="bibr" rid="CR28">28</xref>&#8211;<xref ref-type="bibr" rid="CR31">31</xref></sup> (one of the first known mutations of the S protein, which was shown to prevail in other variants) (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). These independently obtained structures are largely in agreement with each other, revealing both the overall architecture and atomic details of the protein. In the prefusion conformation, the S1 subunit folds into four domains &#8212; the amino-terminal (N-terminal) domain (NTD), the RBD and two carboxy-terminal (C-terminal) domains (CTD1 and CTD2) &#8212; and wraps around the prefusion S2 subunit, which forms a central helical bundle with heptad repeat 1 (HR1) bending back towards the viral membrane (Fig.&#160;<xref rid="Fig2" ref-type="fig">2a</xref>). The three RBDs of the S trimer form the apex of the S protein, which samples two distinct conformations: &#8216;up&#8217; for a receptor-accessible state and &#8216;down&#8217; for a receptor-inaccessible state (Fig.&#160;<xref rid="Fig2" ref-type="fig">2b</xref>&#8211;<xref rid="Fig2" ref-type="fig">d</xref>). In the postfusion state, conformational changes lead to S1 subunit disengagement from S2, and likely its dissociation from S2, while S2 undergoes a cascade of refolding events to form a stable and elongated trimer (Fig.&#160;<xref rid="Fig2" ref-type="fig">2e</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Structures of the S protein, its subdomains and interaction between the RBD and ACE2.</title><p><bold>a</bold> | The full-length SARS-CoV-2 spike (S) protein. Selected subdomain structures are shown in ribbon diagrams below the schematic. Three distinct receptor-binding domain (RBD) antigenic sites (AS-1, AS-2 and AS-3)<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> are indicated in the RBD ribbon diagram. <bold>b</bold>&#8211;<bold>e</bold> | Cryo-electron microscopy structures of detergent-solubilized full-length S trimers from the Wuhan-Hu-1 reference strain in the conformation with three RBDs down (Protein Data Bank (PDB) ID 6XR8; part <bold>b</bold>), the D614G variant in the conformation with three RBDs down (PDB ID 7KRQ; part <bold>c</bold>), the D614G variant in the conformation with one RBD up (PDB ID 7KRR; part <bold>d</bold>) and the postfusion structure of the Wuhan-Hu-1 S2 (PDB ID 6XRA; part <bold>e</bold>). A dramatic conformational change in heptad repeat 1 (HR1) propels insertion of the fusion peptide into the target membrane. In one protomer, in the foreground, subdomains are coloured according to part <bold>a</bold>, and the other two protomers, in the background, are shown in grey or light grey. <bold>f</bold> | The interface between angiotensin-converting enzyme 2 (ACE2; cyan) and bound RBD (red) in the ribbon diagram (PDB ID 6M0J). The receptor-binding motif (RBM) is shown in orange. In the inset, 20 residues of ACE2 and 17 residues from the RBD forming networks of hydrophilic side chain interactions are shown in the stick model. Residues in the RBD that are mutated in the variants of concerns (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) and their interacting residues in ACE2 are highlighted. CH, central helix; CT, cytoplasmic tail; CTD1, carboxy-terminal domain 1; CTD2, carboxy-terminal domain 2; FP, fusion peptide; FPPR, fusion-peptide proximal region; HR2, heptad repeat 2; NTD, amino-terminal domain; S1/S2, furin-cleavage site; S2&#8242;, S2&#8242; cleavage site; TM, transmembrane anchor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e546" position="float" orientation="portrait" xlink:href="41580_2021_418_Fig2_HTML.jpg"/></fig><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Spike protein mutations in SARS-CoV-2 variants</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">WHO label (PANGO lineage)</th><th rowspan="2" colspan="1">GISAID clade (common name)</th><th colspan="4" rowspan="1">Spike protein mutations</th><th rowspan="2" colspan="1">Features</th></tr><tr><th colspan="1" rowspan="1">NTD</th><th colspan="1" rowspan="1">RBD</th><th colspan="1" rowspan="1">Furin site</th><th colspan="1" rowspan="1">Other</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">(B.1)</td><td colspan="1" rowspan="1">D614G (Italy variant)</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">D614G</td><td colspan="1" rowspan="1">Putative ancestor of recent variants: retained in all variants of concern and variants of interest, increased transmissibility<sup><xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR170">170</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Alpha (B.1.1.7)</td><td colspan="1" rowspan="1">GRY (UK variant)</td><td colspan="1" rowspan="1"><p>&#916;69&#8211;70</p><p>&#916;144</p></td><td colspan="1" rowspan="1"><p>(E484K)<sup>a</sup></p><p>(S494P)<sup>a</sup></p><p>N501Y</p></td><td colspan="1" rowspan="1">P681H</td><td colspan="1" rowspan="1"><p>A570D</p><p>D614G</p><p>T716I</p><p>S982A</p><p>D1118H</p><p>(K1191N)<sup>a</sup></p></td><td colspan="1" rowspan="1">Increased transmissibility and viral load<sup><xref ref-type="bibr" rid="CR207">207</xref>,<xref ref-type="bibr" rid="CR208">208</xref></sup>, modest Ab escape<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR190">190</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Beta (B.1.351)</td><td colspan="1" rowspan="1">GH/501Y.V2 (South Africa variant)</td><td colspan="1" rowspan="1"><p>D80A</p><p>D215G</p><p>&#916;241&#8211;243</p></td><td colspan="1" rowspan="1"><p>K417N</p><p>E484K</p><p>N501Y</p></td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1"><p>D614G</p><p>A701V</p></td><td colspan="1" rowspan="1">Increased transmissibility<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>, moderate Ab escape<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR209">209</xref>,<xref ref-type="bibr" rid="CR210">210</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Gamma (P.1)</td><td colspan="1" rowspan="1">GR/501Y.V3 (Brazil variant)</td><td colspan="1" rowspan="1"><p>L18F</p><p>T20N</p><p>P26S</p><p>D138Y</p><p>R190S</p></td><td colspan="1" rowspan="1"><p>K417T</p><p>E484K</p><p>N501Y</p></td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1"><p>D614G</p><p>H655Y</p><p>T1027I</p></td><td colspan="1" rowspan="1">Increased transmissibility<sup><xref ref-type="bibr" rid="CR211">211</xref></sup>, moderate Ab escape<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>, high vaccine breakthrough<sup><xref ref-type="bibr" rid="CR212">212</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Delta (B.1.617.2)</td><td colspan="1" rowspan="1">G/478K.V1 (India variant)</td><td colspan="1" rowspan="1"><p>T19R</p><p>(G142D)<sup>a</sup></p><p>&#916;156&#8211;157</p><p>R158G</p></td><td colspan="1" rowspan="1"><p>(K417N)<sup>b</sup></p><p>L452R</p><p>T478K</p></td><td colspan="1" rowspan="1">P681R</td><td colspan="1" rowspan="1"><p>D614G</p><p>D950N</p></td><td colspan="1" rowspan="1">Increased transmissibility<sup><xref ref-type="bibr" rid="CR187">187</xref></sup>, moderate Ab escape<sup><xref ref-type="bibr" rid="CR43">43</xref>&#8211;<xref ref-type="bibr" rid="CR45">45</xref></sup>, preliminary studies suggest increased S1&#8211;S2 cleavage<sup><xref ref-type="bibr" rid="CR188">188</xref></sup> and vaccine breakthrough<sup><xref ref-type="bibr" rid="CR213">213</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Epsilon (B.1.427) (B.1.429)</td><td colspan="1" rowspan="1">GH/452R.V1 (California variant)</td><td colspan="1" rowspan="1"><p>(S13I)<sup>c</sup></p><p>(W152C)<sup>c</sup></p></td><td colspan="1" rowspan="1">L452R</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">D614G</td><td colspan="1" rowspan="1">Moderate increase in transmissibility<sup>d</sup>, modest Ab escape<sup><xref ref-type="bibr" rid="CR199">199</xref>,<xref ref-type="bibr" rid="CR210">210</xref>,<xref ref-type="bibr" rid="CR214">214</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Eta (B.1.525)</td><td colspan="1" rowspan="1">G/484K.V3</td><td colspan="1" rowspan="1"><p>A67V</p><p>&#916;H69</p><p>&#916;V70</p><p>&#916;144</p></td><td colspan="1" rowspan="1">E484K</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1"><p>D614G</p><p>Q677H</p><p>F888L</p></td><td colspan="1" rowspan="1">Moderate Ab escape expected, owing to E484K</td></tr><tr><td colspan="1" rowspan="1">Iota (B.1.526)</td><td colspan="1" rowspan="1">GH/253G.V1 (New York variant)</td><td colspan="1" rowspan="1"><p>T95I</p><p>D253G</p></td><td colspan="1" rowspan="1">(S477N)<sup>a</sup> (E484K)<sup>a</sup></td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1"><p>(L5F)<sup>a</sup></p><p>D614G</p><p>(A701V)<sup>a</sup></p></td><td colspan="1" rowspan="1">Moderate Ab escape<sup><xref ref-type="bibr" rid="CR215">215</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Kappa (B.1.617.1)</td><td colspan="1" rowspan="1">G/452R.V3 (India variant)</td><td colspan="1" rowspan="1"><p>(T95I)<sup>a</sup></p><p>G142D</p><p>E154K</p></td><td colspan="1" rowspan="1"><p>L452R</p><p>E484Q</p></td><td colspan="1" rowspan="1">P681R</td><td colspan="1" rowspan="1"><p>D614G</p><p>Q1071H</p></td><td colspan="1" rowspan="1">Moderate Ab escape<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR216">216</xref></sup>, preliminary studies suggest increased S1&#8211;S2 cleavage<sup><xref ref-type="bibr" rid="CR188">188</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Lambda (C.37)</td><td colspan="1" rowspan="1">GR/452Q.V1 (Peru variant)</td><td colspan="1" rowspan="1"><p>G75V</p><p>T76I</p><p>&#916;246&#8211;252</p></td><td colspan="1" rowspan="1"><p>L452Q</p><p>F490S</p></td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1"><p>D614G</p><p>T859N</p></td><td colspan="1" rowspan="1">Preliminary studies suggest increased infectivity and minor Ab escape<sup><xref ref-type="bibr" rid="CR49">49</xref></sup></td></tr></tbody></table><table-wrap-foot><p>&#916; indicates deletion. Ab, antibody; GISAID, Global Initiative on Sharing All Influenza Data; NTD, amino-terminal domain; PANGO, Phylogenetic Assignment of Named Global Outbreak; RBD, receptor-binding domain; WHO, World Health Organization. <sup>a</sup>Detected in some but not all sequences. <sup>b</sup>Present in B.1.617.2.1, Delta plus sublineage. <sup>c</sup>Present only in B.1.429 lineage. <sup>d</sup><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://gvn.org/covid-19/epsilon-b-1-427-b-1-429/">https://gvn.org/covid-19/epsilon-b-1-427-b-1-429/</ext-link>.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>The NTD</title><p id="Par9">The NTD is formed mainly by four stacked &#946;-sheets and a number of connecting flexible loops, bearing several <italic toggle="yes">N</italic>-linked glycans (Fig.&#160;<xref rid="Fig2" ref-type="fig">2a</xref>). Whether the NTD plays any functional role in SARS-CoV-2 entry remains unknown. Similar NTDs appear to facilitate the binding of sugar moieties acting as attachment factors by HCoV-OC43 or bovine coronavirus, or the binding to the protein receptor by murine hepatitis virus<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. The NTD of transmissible gastroenteritis virus and MERS-CoV may facilitate prefusion-to-postfusion transition of the S protein<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. Notably, the NTD of SARS-CoV-2 is targeted by some potent neutralizing antibodies (exemplified by 4A8 and 4-8)<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup>, suggesting that it may be functionally important or at least located in the vicinity of other functionally critical regions, such as the RBD. Interestingly, the newly emerged variants often have mutations and deletions in the NTD, rendering them resistant to these neutralizing antibodies<sup><xref ref-type="bibr" rid="CR38">38</xref>&#8211;<xref ref-type="bibr" rid="CR49">49</xref></sup>.</p></sec><sec id="Sec5"><title>The RBD</title><p id="Par10">The RBD has two subdomains (Fig.&#160;<xref rid="Fig2" ref-type="fig">2a</xref>): a core structure formed by a five-stranded antiparallel &#946;-sheet covered with short connecting &#945;-helices on both sides, and an extended loop, named the &#8216;receptor-binding motif&#8217; (RBM), which wraps around one edge of the core structure and makes all the contacts with ACE2 (refs<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>). In the down conformation of the prefusion S trimer, a single RBD packs against the central helical bundle of S2 and the two other RBDs, while leaning on CTD1 from the same protomer and the NTD from a neighbouring protomer (Fig.&#160;<xref rid="Fig2" ref-type="fig">2b</xref>,<xref rid="Fig2" ref-type="fig">c</xref>). This configuration partially occludes the RBM, making it inaccessible to the receptor ACE2. When the RBD flips to the up conformation and fully exposes the RBM (Fig.&#160;<xref rid="Fig2" ref-type="fig">2d</xref>), the adjacent CTD1 and NTD also shift away to accommodate the RBD movement. Thus, the transition of the RBD from the down conformation to the up conformation is a critical step before the receptor can fully engage, and the one-RBD-up conformation appears to be a stable intermediate state. RBDs from other <xref rid="Glos10" ref-type="list">sarbecoviruses</xref> can be categorized into two distinct groups: human ACE2 (hACE2) binders and non-hACE2 binders<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. They are likely to fold similarly because of the high degree of sequence identity in the core subdomain, but variations at the ACE2-binding interface in the RBM of the non-hACE2 binders can explain their inability to use hACE2 as an entry receptor<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>.</p><p id="Par11">Importantly, the RBD is also the primary target of the neutralizing antibodies elicited by natural infection or vaccination (Box&#160;<xref rid="Sec6" ref-type="sec">1</xref>). There are three major non-overlapping antigenic sites on the RBD<sup><xref ref-type="bibr" rid="CR52">52</xref></sup> (Fig.&#160;<xref rid="Fig2" ref-type="fig">2a</xref>). Most RBD-directed neutralizing antibodies, including REGN10933 (casirivimab) and C144, recognize the tip region of the RBM, and they often show remarkable potency blocking ACE2 engagement by direct competition<sup><xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR54">54</xref></sup>. Another site lies on the exposed surface of the RBD when it is in the down configuration, and is targeted by antibodies such as REGN10987 (imdevimab) and S309 (refs<sup><xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR55">55</xref></sup>). The third site, often referred to as a &#8216;cryptic supersite&#8217;, targeted by CR3022 (ref.<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>), is on the buried side of the RBD and is fully accessible only when the domain is in the up conformation. Together, these sites comprise the epitopes of majority of neutralizing antibodies to SARS-CoV-2, as discussed later.</p></sec><sec id="Sec6"><boxed-text position="float" orientation="portrait"><label>Box 1 Antibodies and antibody-like entry inhibitors for SARS-CoV-2</label><p id="Par12">Of the various stages of the virus life cycle, the entry step is one of the most attractive therapeutic targets, not only because it initiates infection but also because the cellular receptors and viral entry proteins are accessible from the extracellular space. Currently, however, the only FDA-approved antiviral drug for COVID-19, remdesivir, acts on the viral RNA-dependent RNA polymerase inside the cell rather than at the point of entry<sup><xref ref-type="bibr" rid="CR233">233</xref></sup>. Camostat mesylate, a transmembrane protease, serine 2 (TMPRSS2) inhibitor, is currently under evaluation<sup><xref ref-type="bibr" rid="CR234">234</xref></sup>. A multitude of other small molecules were found to inhibit SARS-CoV-2 entry in vitro via various mechanisms<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR235">235</xref>&#8211;<xref ref-type="bibr" rid="CR239">239</xref></sup>, but it is premature to predict their utility because of toxicity and/or uncertain in vivo efficacy. Currently, the use of antibodies and antibody-like products is the most promising strategy to therapeutically target the entry of SARS-CoV-2.</p><p id="Par13">
<bold>Immune plasma</bold>
</p><p id="Par14">The earliest available therapy for COVID-19 was infusion of convalescent plasma. Studies show that convalescent plasma may offer modest protection against progression to severe disease or death when administered early in the course of infection<sup><xref ref-type="bibr" rid="CR240">240</xref>,<xref ref-type="bibr" rid="CR241">241</xref></sup>, but most trials in hospitalized patients showed no significant benefit<sup><xref ref-type="bibr" rid="CR242">242</xref>&#8211;<xref ref-type="bibr" rid="CR244">244</xref></sup>. Moreover, plasma therapy is complicated by the wide variation in neutralizing activity of donor plasma<sup><xref ref-type="bibr" rid="CR245">245</xref></sup>.</p><p id="Par15">
<bold>Antibodies targeting the spike protein</bold>
</p><p id="Par16">Monoclonal antibodies and antibody derivatives targeting SARS-CoV-2 have been intensely studied in vitro<sup><xref ref-type="bibr" rid="CR246">246</xref>&#8211;<xref ref-type="bibr" rid="CR249">249</xref></sup>, and have been brought to market for clinical use by Regeneron and Eli Lilly. One serious problem associated with these antibodies is fast-emerging resistant mutations<sup><xref ref-type="bibr" rid="CR194">194</xref></sup>. For this reason, Eli Lilly&#8217;s bamlanivimab, initially authorized by the FDA as monotherapy<sup><xref ref-type="bibr" rid="CR250">250</xref></sup>, is now available only as a combination with another antibody with a non-overlapping epitope, etesevimab<sup><xref ref-type="bibr" rid="CR251">251</xref></sup>. Regeneron&#8217;s casirivimab and imdevimab were authorized as a combination therapy, and thus far no report has indicated reduced neutralization towards recently emerged immune-escape variants. Propagation of SARS-CoV-2 in vitro or in hamsters in the presence of this antibody combination also did not elicit escape variants, although additional studies are necessary owing to the short duration of the study<sup><xref ref-type="bibr" rid="CR196">196</xref></sup>. Neither cocktail is authorized for use in severely ill or hospitalized patients owing to the unfavourable risk&#8211;benefit profile in this population<sup><xref ref-type="bibr" rid="CR252">252</xref></sup>.</p><p id="Par17">
<bold>Antibodies targeting ACE2</bold>
</p><p id="Par18">In contrast to anti-spike protein antibodies, antibodies targeting human angiotensin-converting enzyme 2 (ACE2) may be advantageous in that viral escape cannot arise because their target epitope is on the host cell<sup><xref ref-type="bibr" rid="CR253">253</xref></sup>. Such antibodies are not expected to interfere with the function of ACE2, because the SARS-CoV-2 binding region on ACE2 does not overlap with the enzyme&#8217;s active site. However, as antibodies are naturally bivalent, they likely crosslink and downregulate ACE2, which can disrupt the renin&#8211;angiotensin&#8211;aldosterone system.</p><p id="Par19">
<bold>ACE2 mimetics</bold>
</p><p id="Par20">ACE2 mimetics, such as ACE2 ectodomain, its Fc-fusion form and their variants selected for higher affinity, can prevent the initial steps of receptor engagement by the virus<sup><xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR254">254</xref>&#8211;<xref ref-type="bibr" rid="CR257">257</xref></sup>. Like ACE2-targeting antibodies, viruses cannot evade them without sacrificing their ability to bind the receptor. On the one hand, catalytically inactive forms of ACE2 mimetics, in which residues involved in binding angiotensin I and angiotensin II are mutated, can be used as therapeutics without perturbing the renin&#8211;angiotensin&#8211;aldosterone system<sup><xref ref-type="bibr" rid="CR254">254</xref></sup>. One such construct showed enhanced rather than reduced activity against variants of concern<sup><xref ref-type="bibr" rid="CR257">257</xref></sup>. On the other hand, catalytically active ACE2 mimetics may be more beneficial in treating acute respiratory distress syndrome induced by SARS-CoV-2-mediated downregulation of cellular ACE2 (refs<sup><xref ref-type="bibr" rid="CR258">258</xref>,<xref ref-type="bibr" rid="CR259">259</xref></sup>).</p></boxed-text></sec><sec id="Sec7"><title>The C-terminal domains</title><p id="Par21">C-terminal domains are formed primarily by &#946;-structures. The RBD appears to be an insertion between two antiparallel &#946;-strands in CTD1, and CTD1 can also be viewed as an insertion between two antiparallel &#946;-strands in CTD2 (Fig.&#160;<xref rid="Fig2" ref-type="fig">2a</xref>). Thus, a continuous strand (residues 306&#8211;330) runs through both CTD1 and CTD2, connecting the NTD and the RBD on its two ends. CTD1, packed underneath the RBD, needs to rotate outwards with the RBD in the flipping-up transition into the receptor-accessible state. A structural element in S2, named the &#8216;fusion-peptide proximal region&#8217; (FPPR), abutting the opposite side&#160;of CTD1 from the RBD, appears to help clamp down the RBD and stabilize the closed conformation of the S trimer<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. Therefore, CTD1 appears to be a structural relay between the RBD and the FPPR: it senses the changes in the RBD and the FPPR, which are located on either side of CTD1.</p><p id="Par22">CTD2 is formed by two stacked &#946;-sheets, each containing four strands, with a fifth strand in one sheet contributed by the connecting strand between the NTD and the RBD (Fig.&#160;<xref rid="Fig2" ref-type="fig">2a</xref>). In the other sheet, an interstrand loop contains the furin-cleavage site at the S1&#8211;S2 boundary, and one strand is the N-terminal segment of S2. A structural element, designated the &#8216;630 loop&#8217;<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>, in CTD2 is largely disordered in the S trimer of the Wuhan-Hu-1 strain (Fig.&#160;<xref rid="Fig2" ref-type="fig">2b</xref>) but is ordered in the presence of the D614G mutation (Fig.&#160;<xref rid="Fig2" ref-type="fig">2c</xref>) and plays an important role in stabilizing the S trimer, as discussed later. Thus, CTD2 is another key component for the structural rearrangements of the S protein required for membrane fusion.</p></sec><sec id="Sec8"><title>The S2 subunit</title><p id="Par23">In the prefusion conformation (Fig.&#160;<xref rid="Fig2" ref-type="fig">2a</xref>), the S2 subunit adopts a conformation with most of the polypeptide chain packed around a three-stranded coiled coil formed by the central helices<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. In particular, the coiled coil and part of HR1 together with another helix formed by residues 758&#8211;784 assemble into a nine-helix bundle, which likely contributes to overall stability of the S protein. The second half of HR1 and the so-called connector domain, which links the central helix and C-terminal heptad repeat 2 (HR2)<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>, surround the bottom of the coiled coil, partially protecting the fusion peptide. The FPPR, directly connected to the fusion&#160;peptide, tucks underneath CTD1 from the neighbouring protomer and also makes contacts with CTD2 of the same protomer (Fig.&#160;<xref rid="Fig2" ref-type="fig">2b</xref>&#8211;<xref rid="Fig2" ref-type="fig">d</xref>). The C-terminal segments, including HR2, the transmembrane domain and the cytoplasmic tail, are largely disordered in the prefusion S trimer structures, except for some low-resolution density in certain reconstructions<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>.</p><p id="Par24">In the postfusion S2 structure (Fig.&#160;<xref rid="Fig2" ref-type="fig">2e</xref>), HR1 and the central helix form an unusually long central three-stranded coiled coil (~180&#8201;&#197;)<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, almost identical to the S2 structures of SARS-CoV and mouse hepatitis virus<sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup> The N-terminal region of HR2 adopts a one-turn helical conformation and packs against the groove of the HR1 coiled coil; the C-terminal region of HR2 forms a longer helix that makes up a six-helix bundle structure with the rest of the HR1 coiled coil, forming a stable rigid postfusion structure. The postfusion S2 unexpectedly aligns <italic toggle="yes">N</italic>-linked glycans along the long axis, with four of them spaced regularly on the same side of the trimer<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Comparison of the prefusion and postfusion states of S2 suggests that HR1 undergoes a dramatic refolding transition that can insert the fusion peptide into the target cell membrane, similar to a mechanism proposed for other coronaviruses<sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup>.</p></sec></sec><sec id="Sec9"><title>SARS-CoV-2 receptor ACE2</title><p id="Par25">ACE2 is an 805-amino acid carboxypeptidase that removes a single amino acid from the C terminus of its substrates. It consists of a single metallopeptidase domain in the first half that contains the HEXXH zinc-binding motif at the catalytic site and shares homology with <xref rid="Glos11" ref-type="list">angiotensin-converting enzyme</xref> (ACE), and a C-terminal half including the transmembrane domain that shares homology with <xref rid="Glos12" ref-type="list">collectrin</xref><sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup>. Integral to the <xref rid="Glos13" ref-type="list">renin&#8211;angiotensin&#8211;aldosterone system</xref>, the primary role of ACE2 in normal physiology is to convert angiotensin I and angiotensin II, generated by renin and ACE, into angiotensin-(1&#8211;9) and angiotensin-(1&#8211;7), respectively<sup><xref ref-type="bibr" rid="CR60">60</xref>&#8211;<xref ref-type="bibr" rid="CR62">62</xref></sup>. Like ACE2 for SARS-CoV-2, the obligate receptors for several other coronaviruses are also proteases (DPP4 (also known as CD26) for MERS-CoV and APN for HCoV-229E)<sup><xref ref-type="bibr" rid="CR63">63</xref>&#8211;<xref ref-type="bibr" rid="CR65">65</xref></sup>. Interestingly, the catalytic activity of these receptors neither is necessary for their receptor function nor overlaps with the virus-binding site. Consistently, small-molecule inhibitors of the catalytic site of ACE2 do not block infection by SARS-CoV<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. Nonetheless, studies have shown that downregulation of ACE2 resulting from SARS-CoV infection contributes to disease severity by perturbing the renin&#8211;angiotensin&#8211;aldosterone system<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. The same is presumed for SARS-CoV-2, given that SARS-CoV and SARS-CoV-2 engage ACE2 in the same manner.</p><sec id="Sec10"><title>Interaction between the S protein and the receptor</title><p id="Par26">The interface between the RBD of the S protein and ACE2 is formed primarily by a gently concave outer surface of the extended RBM and the N-terminal helix of the receptor<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup> (Fig.&#160;<xref rid="Fig2" ref-type="fig">2f</xref>). There are 20 residues of ACE2 and 17 residues from the RBD forming networks of hydrophilic, side chain interactions. Of the latter, residues Lys417, Leu452, Glu484 and Asn501 are those that have been mutated in the newly emerged SARS-CoV-2 variants of concern<sup><xref ref-type="bibr" rid="CR44">44</xref>&#8211;<xref ref-type="bibr" rid="CR49">49</xref></sup> (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>), and may confer both increased receptor binding and/or antibody resistance. As expected, the mode of ACE2 binding is almost identical between the SARS-CoV and SARS-CoV-2 RBDs<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>. Many interacting residues are identical or have only conservative substitutions between the two RBDs. Several positions with non-conservative substitutions can still maintain similar interactions. The only extra ACE2-interacting residue in SARS-CoV-2 is Lys417, which forms a salt bridge with Asp30 of ACE2 (Fig.&#160;<xref rid="Fig2" ref-type="fig">2f</xref>). Interestingly, despite the higher affinity of the SARS-CoV-2 RBD for ACE2 compared with the SARS-CoV RBD, the SARS-CoV-2 S protein trimer does not bind ACE2 as efficiently as does the SARS-CoV S protein trimer<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>. This apparent paradox, a consequence of the inherent instability of the original SARS-CoV-2 (Wuhan-Hu-1) S protein, is further discussed together with the D614G mutation later. Other shared features of the RBD&#8211;ACE2 interfaces between the two viruses include the role of multiple tyrosine residues forming hydrogen bonds at the interface and a common disulfide-bonded RBD core<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>.</p><p id="Par27">The structures of the soluble SARS-CoV-2 S trimer in complex with monomeric ACE2 confirm that the receptor interacts with the RBD in its up conformation<sup><xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR69">69</xref></sup>, which is consistent with previous findings with ACE2 binding to the SARS-CoV S protein<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>. While the NTD shifts outwards slightly, the S2 subunit remains largely unchanged upon ACE2 binding.</p></sec><sec id="Sec11"><title>ACE2 expression and the putative impact of comorbidities</title><p id="Par28">Analysis of animal models and human transcriptome databases suggests that ACE2 expression in the lower lung is relatively limited to <xref rid="Glos14" ref-type="list">type II alveolar cells</xref>, but is higher in the upper bronchial epithelia and much higher in the nasal epithelium, especially in the <xref rid="Glos15" ref-type="list">ciliated cells</xref><sup><xref ref-type="bibr" rid="CR71">71</xref>&#8211;<xref ref-type="bibr" rid="CR76">76</xref></sup>. This difference in ACE2 expression level in the respiratory tract is mirrored by the SARS-CoV-2 infection gradient, with nasal ciliated cells being primary targets for SARS-CoV-2 replication in the early stage of infection<sup><xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR75">75</xref></sup>. Despite the respiratory route being dominant in SARS-CoV-2 infection, the highest levels of ACE2 expression are found in the small intestine, testis, kidney, heart muscle, colon and thyroid gland<sup><xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR77">77</xref></sup>. Cardiac infection by SARS-CoV-2 was frequently found in autopsy cases<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>, and the presence of ACE2 in colon and kidney cells has been suggested as an explanation for gastrointestinal and renal complications of SARS-CoV-2 infection. ACE2 expression in the gastrointestinal tract is consistent with the observation that many coronaviruses, including sarbecoviruses, are transmitted via the faecal&#8211;oral route as well as the respiratory route. Inflammatory cytokines released in severe COVID-19, such as IL-1&#946; and type I and type III interferons, can upregulate ACE2 expression, potentially establishing a positive-feedback loop for viral replication<sup><xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR79">79</xref>&#8211;<xref ref-type="bibr" rid="CR81">81</xref></sup>. However, their effect on disease severity is unknown. Moreover, a recent report indicates that interferon-stimulated expression of ACE2 yields a truncated isoform that cannot support SARS-CoV-2 binding<sup><xref ref-type="bibr" rid="CR82">82</xref></sup>.</p><p id="Par29">Several health comorbidities, including hypertension, hyperlipidaemia, diabetes, chronic pulmonary diseases, old age and smoking, are risk factors for COVID-19. A&#160;number of these factors have been proposed to modulate ACE2 expression. Differences in ACE2 levels associated with age and sex are controversial; advanced age has been both positively<sup><xref ref-type="bibr" rid="CR83">83</xref>,<xref ref-type="bibr" rid="CR84">84</xref></sup> and negatively<sup><xref ref-type="bibr" rid="CR85">85</xref></sup> correlated with ACE2 expression, while another independent study found no significant effect<sup><xref ref-type="bibr" rid="CR80">80</xref></sup>. Male sex has similarly been associated with higher ACE2 expression in some studies<sup><xref ref-type="bibr" rid="CR84">84</xref></sup> but not others<sup><xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR85">85</xref></sup>. Widely accepted epidemiological data indicate that a history of smoking tobacco increases the risk of severe disease<sup><xref ref-type="bibr" rid="CR86">86</xref>,<xref ref-type="bibr" rid="CR87">87</xref></sup>. However, whether smoking causes upregulation of ACE2 and is associated with enhanced infection is unclear. Many biochemical studies have shown that ACE2 expression is increased in lung tissue samples from smokers and patients with <xref rid="Glos16" ref-type="list">chronic obstructive pulmonary disease</xref><sup><xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR88">88</xref>,<xref ref-type="bibr" rid="CR89">89</xref></sup> and also in mouse lungs exposed to cigarette smoking<sup><xref ref-type="bibr" rid="CR80">80</xref></sup>. However, other studies indicated that ACE2 expression in the airway is not affected by smoking<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>, and that smoking is not a significant epidemiological risk factor for COVID-19 (refs<sup><xref ref-type="bibr" rid="CR90">90</xref>,<xref ref-type="bibr" rid="CR91">91</xref></sup>). A limited number of studies showed that diabetes mellitus is associated with increased ACE2 expression in human sputum cells and in murine kidney tissue<sup><xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR92">92</xref></sup> and that cystic fibrosis is associated with ACE2 (and TMPRSS2) upregulation in human lung specimens<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>. It was initially speculated that common antihypertensive drugs such as ACE inhibitors and angiotensin receptor blockers could upregulate ACE2 expression<sup><xref ref-type="bibr" rid="CR93">93</xref></sup>, raising concern that use of these agents could increase disease severity<sup><xref ref-type="bibr" rid="CR94">94</xref>,<xref ref-type="bibr" rid="CR95">95</xref></sup>. Although this idea is consistent with the association between hypertension and severer COVID-19 outcomes, recent studies have refuted this hypothesis<sup><xref ref-type="bibr" rid="CR76">76</xref>,<xref ref-type="bibr" rid="CR91">91</xref>,<xref ref-type="bibr" rid="CR96">96</xref>,<xref ref-type="bibr" rid="CR97">97</xref></sup>. Thus, to date, no comorbidity has been unambiguously associated with ACE2 expression level.</p></sec><sec id="Sec12"><title>ACE2 orthologues in potential reservoir species</title><p id="Par30">Similarities in virus-binding hotspots of ACE2 and its orthologues in reservoir animal species contribute to the zoonotic potential of sarbecoviruses. Horseshoe bats of the genus <italic toggle="yes">Rhinolophus</italic> are the presumed long-term reservoirs of SARS-CoV and SARS-CoV-2, but it remains unclear exactly which species in the genus serves as the most recent bat host of each virus<sup><xref ref-type="bibr" rid="CR98">98</xref></sup>. A mammalian intermediate host is thought to facilitate transmission of both viruses to humans. Accordingly, SARS-CoV has been isolated from palm civets (<italic toggle="yes">Paguma larvata</italic>) and raccoon dogs (<italic toggle="yes">Nyctereutes procyonoides</italic>)<sup><xref ref-type="bibr" rid="CR99">99</xref></sup>, and viruses close to SARS-CoV-2 were isolated from pangolins (<italic toggle="yes">Manis javanica</italic>)<sup><xref ref-type="bibr" rid="CR100">100</xref>&#8211;<xref ref-type="bibr" rid="CR102">102</xref></sup>. The significance of receptor adaptation during host-jumping from an intermediate host to humans is underscored by evidence that two independent zoonotic events gave rise to the two SARS outbreaks between 2002 and 2004 with markedly different disease severity. While the 2002&#8211;2003 SARS epidemic resulted in nearly 10% mortality, the outbreak in 2003&#8211;2004 resulted in a much milder disease<sup><xref ref-type="bibr" rid="CR103">103</xref></sup>. Analysis of the S protein of the virus isolates from both outbreaks revealed that reduced disease severity of the second outbreak was in part due to insufficient adaptation of the S protein to hACE2, as shown by lower affinity<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. This affinity difference was mapped to a single residue in the RBD, foreshadowing the impact of RBD mutations in SARS-CoV-2 on transmissibility and disease severity.</p><p id="Par31">Viruses closely related to SARS-CoV-2 have been isolated from the horseshoe bat, <italic toggle="yes">Rhinolophus affinis</italic>, including SARS-like betacoronavirus RaTG13, which shares 96% nucleotide identity with SARS-CoV-2 (ref.<sup><xref ref-type="bibr" rid="CR104">104</xref></sup>). Investigators evaluated the receptor function of a wide array of bat ACE2 orthologues and found that only 9 of 46 supported the entry by SARS-CoV-2 pseudoviruses<sup><xref ref-type="bibr" rid="CR105">105</xref></sup>. Replacement of five residues in hACE2 with residues originating from the SARS-CoV-2-competent ACE2 orthologues of <italic toggle="yes">Rhinolophus</italic> spp. increased its binding affinity for the SARS-CoV-2 RBD<sup><xref ref-type="bibr" rid="CR98">98</xref></sup>. Although not fully conclusive, these data are consistent with a <italic toggle="yes">Rhinolophus</italic> origin of SARS-CoV-2. Phylogenetic analysis and confirmatory infection studies have shown that ACE2 orthologues from a wide range of mammals, including domestic animals and livestock, support SARS-CoV-2 infection, suggesting that many animals have the potential to act as intermediate hosts as well<sup><xref ref-type="bibr" rid="CR106">106</xref></sup>.</p></sec></sec><sec id="Sec13"><title>Additional host entry factors</title><p id="Par32">In addition to ACE2, several molecules have been suggested to serve as alternative receptors for SARS-CoV and SARS-CoV-2. These include C-type <xref rid="Glos17" ref-type="list">lectins</xref>, DC-SIGN and L-SIGN<sup><xref ref-type="bibr" rid="CR107">107</xref>&#8211;<xref ref-type="bibr" rid="CR109">109</xref></sup>. Lectins are involved in the recognition of a broad range of pathogens<sup><xref ref-type="bibr" rid="CR110">110</xref></sup> and mediate intercellular adhesion<sup><xref ref-type="bibr" rid="CR111">111</xref></sup>. They bind a wide range of viruses by recognizing the glycans on the virion surface, often promoting viral entry by allowing the virus to attach to the target cell. Likewise, TIM1 and AXL were also suggested to be alternative SARS-CoV-2 receptors<sup><xref ref-type="bibr" rid="CR112">112</xref>,<xref ref-type="bibr" rid="CR113">113</xref></sup>. As members of phosphatidylserine receptor families, TIM and TAM, respectively, they enhance the entry of a wide range of enveloped viruses by binding to phosphatidylserine on the virion membrane<sup><xref ref-type="bibr" rid="CR114">114</xref>&#8211;<xref ref-type="bibr" rid="CR116">116</xref></sup>. Although lectins and phosphatidylserine receptors increase viral entry, they are non-specific and do not support efficient infection by SARS-CoV or SARS-CoV-2 in the absence of ACE2 (refs<sup><xref ref-type="bibr" rid="CR115">115</xref>,<xref ref-type="bibr" rid="CR117">117</xref></sup>), and thus &#8216;attachment factors&#8217; would better describe those molecules.</p><p id="Par33">Similarly, CD147, a transmembrane glycoprotein expressed ubiquitously in epithelial and immune cells, was proposed to be an alternative receptor for SARS-CoV and SARS-CoV-2 infection<sup><xref ref-type="bibr" rid="CR118">118</xref>,<xref ref-type="bibr" rid="CR119">119</xref></sup>. Although a modest increase in viral entry was observed with higher levels of CD147, and although its upregulation was observed in obesity and diabetes<sup><xref ref-type="bibr" rid="CR120">120</xref></sup>, which are potential risk factors for severe COVID-19, the role of CD147 in SARS-CoV-2 infection has been disputed on the basis of the inability of CD147 to bind the S protein<sup><xref ref-type="bibr" rid="CR121">121</xref></sup>. Two groups identified <xref rid="Glos18" ref-type="list">neuropilin 1</xref> (NRP1) as a host factor for SARS-CoV-2 (refs<sup><xref ref-type="bibr" rid="CR122">122</xref>,<xref ref-type="bibr" rid="CR123">123</xref></sup>). Although NRP1 is expressed in olfactory and respiratory epithelial cells<sup><xref ref-type="bibr" rid="CR122">122</xref></sup>, its expression is low in ciliated cells, the primary target cells for SARS-CoV-2 in the airway, while it is high in <xref rid="Glos19" ref-type="list">goblet cells</xref>, which are not susceptible to SARS-CoV-2 (refs<sup><xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR75">75</xref></sup>). Nonetheless, NRP1 was shown to enhance TMPRSS2-mediated entry (see the next section) of wild-type SARS-CoV-2 but not that of mutant virus that lacks the multibasic furin-cleavage site<sup><xref ref-type="bibr" rid="CR122">122</xref></sup>. NRP1 was also shown to bind S1 through the multibasic furin-cleavage site and to promote S1 shedding and to expose the S2&#8242;&#160;site to TMPRSS2 (ref.<sup><xref ref-type="bibr" rid="CR124">124</xref></sup>). Recently, the structure of ACE2 in complex with a neutral amino acid transporter, B0AT1, was analysed by cryo-EM in the presence and absence of the SARS-CoV-2 S protein<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. ACE2 was previously shown to be essential for B0AT1 expression in the small intestine<sup><xref ref-type="bibr" rid="CR125">125</xref></sup>. While B0AT1 is expressed in the gastrointestinal tract and kidney, it is not present in the&#160;lung. However, a B0AT1 homologue in the lung might contribute to SARS-CoV-2 infection. Additional studies are warranted to confirm the role of NRP1 and B0AT1 in SARS-CoV-2 infection.</p></sec><sec id="Sec14"><title>SARS-CoV-2 entry process</title><p id="Par34">Viral entry proteins must fold into an energetically stable state, and yet must undergo a subsequent conformational transition that provides sufficient energy to overcome the natural repulsion between the virus and the cellular membranes. Therefore, the S protein transitions to a so-called metastable state, a state prone to transformation to a lower-energy state, before membrane fusion. Like in SARS-CoV and other coronaviruses, this S protein transition is enabled through two proteolytic cleavage steps following ACE2 engagement. The first of these is localized to the S1&#8211;S2 boundary, and&#160;the second is localized to the S2&#8242; site in the S2 subunit. For SARS-CoV, both sites are cleaved by proteases in the target cell. In the case of SARS-CoV-2, the S1&#8211;S2 boundary is cleaved by furin in the virus-producer cell, whereas the S2&#8242; site cleavage still requires target-cell proteases. Cell entry by both viruses is therefore dependent on the target-cell proteases, and TMPRSS2 and cathepsin L are the two major proteases involved in S protein activation. As TMPRSS2 is present at the cell surface, TMPRSS2-mediated S protein activation occurs at the plasma membrane, whereas cathepsin-mediated activation occurs in the endolysosome (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Two distinct SARS-CoV-2 entry pathways.</title><p>Two spike (S) protein cleavage events are typically necessary for the coronavirus entry process: one at the junction of the S1 and S2 subunits and the other at the S2&#8242; site, internal to the S2 subunit. In the case of SARS-CoV-2, the polybasic sequence at the S1&#8211;S2 boundary is cleaved during virus maturation in an infected cell, but the S2&#8242; site is cleaved at the target cell following angiotensin-converting enzyme 2 (ACE2) binding. Virus binding to ACE2 (step 1) induces conformational changes in the S1 subunit and exposes the S2&#8242; cleavage site in the S2 subunit. Depending on the entry route taken by SARS-CoV-2, the S2&#8242; site is cleaved by different proteases. Left: If the target cell expresses insufficient transmembrane protease, serine 2 (TMPRSS2) or if a virus&#8211;ACE2 complex does not encounter TMPRSS2, the virus&#8211;ACE2 complex is internalized via clathrin-mediated endocytosis (step 2) into the endolysosomes, where S2&#8242; cleavage is performed by cathepsins, which require an acidic environment for their activity (steps 3 and 4). Right: In the presence of TMPRSS2, S2&#8242; cleavage occurs at the cell surface (step 2). In both entry pathways, cleavage of the S2&#8242; site exposes the fusion peptide (FP) and dissociation of S1 from S2 induces dramatic conformational changes in the S2 subunit, especially in heptad repeat 1, propelling the fusion peptide forward into the target membrane, initiating membrane fusion (step 5 on the left and step 3 on the right). Fusion between viral and cellular membranes forms a fusion pore through which viral RNA is released into the host cell cytoplasm for uncoating and replication (step 6 on the left and step 4 on the right). Several agents disrupt interaction between the S protein and ACE2: ACE2 mimetics, therapeutic monoclonal antibodies targeting the neutralizing epitopes on the S protein and antibodies elicited by vaccination block virus binding to ACE2 and thus inhibit both entry pathways. By contrast, strategies targeting post-receptor-binding steps differ between the two pathways. Being a serine protease inhibitor, camostat mesylate restricts the TMPRSS2-mediated entry pathway. Hydroxychloroquine and chloroquine block endosomal acidification, which is necessary for cathepsin activity, and thus restrict the cathepsin-mediated entry pathway.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1825" position="float" orientation="portrait" xlink:href="41580_2021_418_Fig3_HTML.jpg"/></fig></p><sec id="Sec15"><title>Cleavage of the S protein S1&#8211;S2 boundary by furin</title><p id="Par35">The presence of a multibasic site (Arg-Arg-Ala-Arg) located at the S1&#8211;S2 junction, which is cleaved by furin (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>), distinguishes SARS-CoV-2 from SARS-CoV and all other known sarbecoviruses whose S protein is not cleaved by furin-like proteases during virus maturation in the infected cell. Cleavage of the S1&#8211;S2 boundary is a prerequisite for the cleavage of the S2&#8242; site<sup><xref ref-type="bibr" rid="CR126">126</xref></sup>, and both cleavage events are essential to initiate the membrane-fusion process. The entry glycoproteins of many viruses, including HIV-1 and avian influenza viruses, are cleaved by furin, but such cleavage does not destabilize the entry glycoprotein; the two subunits are associated via a stable interaction. By contrast, the S1 subunit of human SARS-CoV-2 Wuhan-Hu-1 strain is easily shed from the S2 subunit and thereupon assumes a premature postfusion conformation of the S2 trimer, a non-functional form of the S protein (Fig.&#160;<xref rid="Fig2" ref-type="fig">2e</xref>). This perplexing observation suggests that the acquisition of a furin-cleavage site by SARS-CoV-2 may have been a recent event. While it would have been relatively straightforward for the virus to have eliminated this furin-cleavage site and depend on the target-cell proteases as does SARS-CoV, SARS-CoV-2 rather acquired a different mutation, D614G, to stabilize the S protein and slow S1 shedding<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR127">127</xref></sup>. This steadfast retention of the destabilizing furin site indicates that this site is important for virus fitness in human hosts. Indeed, the furin site was recently shown to be an important determinant for SARS-CoV-2 transmission among co-housed ferrets<sup><xref ref-type="bibr" rid="CR128">128</xref></sup>.</p></sec><sec id="Sec16"><title>Role of TMPRSS2 in viral entry</title><p id="Par36">After the S1&#8211;S2 boundary is cleaved, the S2&#8242; site must also be cleaved to fully activate the fusion process either by TMPRSS2 on the cell surface or by cathepsins in the endosomes (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). TMPRSS2 is a <xref rid="Glos20" ref-type="list">type II transmembrane protein</xref> with serine protease activity whose major physiological role and substrate specificity are not well defined. Nonetheless, its role in respiratory virus infection, especially for influenza viruses<sup><xref ref-type="bibr" rid="CR129">129</xref>&#8211;<xref ref-type="bibr" rid="CR131">131</xref></sup> and SARS coronaviruses<sup><xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref></sup>, is well established. TMPRSS2 is found in the gastrointestinal, respiratory and urogenital epithelium<sup><xref ref-type="bibr" rid="CR132">132</xref>,<xref ref-type="bibr" rid="CR133">133</xref></sup>. Among these tissues, three major cell types co-express TMPRSS2 and ACE2 &#8212; type II pneumocytes, ileal absorptive enterocytes and nasal goblet secretory cells<sup><xref ref-type="bibr" rid="CR81">81</xref></sup> &#8212; although other studies showed that nasal ciliated cells but not nasal goblet cells express ACE2 (refs<sup><xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR76">76</xref></sup>) or that both cells express ACE2 at high levels<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. ACE2 expression in the lower airway is limited, but ACE2 is expressed at a higher level in the upper airway, and indeed many airway cells that express ACE2 also express TMPRSS2 (refs<sup><xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR134">134</xref>&#8211;<xref ref-type="bibr" rid="CR136">136</xref></sup>). While TMPRSS2 is the most frequently studied protease in coronavirus entry, other serine proteases present in the lung, including human airway trypsin-like protease (HAT), TMPRSS4, TMPRSS11A, TMPRSS11E and matriptase, as well as secreted neutrophil elastase, appear to contribute to infection by many respiratory viruses<sup><xref ref-type="bibr" rid="CR137">137</xref></sup>. Studies on their involvement in viral infection in vivo will provide further insight into the SARS-CoV-2 entry pathway and the means to inhibit the process.</p><p id="Par37">Although both viruses utilize TMPRSS2, SARS-CoV is less dependent on TMPRSS2 than is SARS-CoV-2 (refs<sup><xref ref-type="bibr" rid="CR138">138</xref>,<xref ref-type="bibr" rid="CR139">139</xref></sup>). One determining factor might be the presence or absence of a furin site at the S1&#8211;S2 boundary<sup><xref ref-type="bibr" rid="CR140">140</xref></sup>. It&#160;is possible that the sequence of the S1&#8211;S2 junction of the SARS-CoV S protein is not a suitable substrate for TMPRSS2 but is more easily cleaved by cathepsins. This explanation is consistent with the observation that replacing the SARS-CoV-2 furin site with the equivalent sequence of SARS-CoV or RaTG13 virus from horseshoe bats, containing no multibasic site, prevented efficient SARS-CoV-2 infection of TMPRSS2<sup>+</sup> human airway cells<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>.</p></sec><sec id="Sec17"><title>Role of cathepsins in viral entry</title><p id="Par38">Although SARS-CoV-2 prefers activation by TMPRSS2, cleavage of the S2&#8242; site can also be mediated by cathepsins, especially cathepsin L (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). If the target cells express insufficient TMPRSS2 or if a virus&#8211;ACE2 complex does not encounter TMPRSS2, ACE2-bound virus is internalized via clathrin-mediated endocytosis<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup> into the late endolysosome, where the S2&#8242; site is cleaved by cathepsins. Presumably owing to multiple ligations to ACE2, binding of SARS-CoV, SARS-CoV-2 or purified S protein induces ACE2 endocytosis<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>. The role of cathepsins in processing the S2&#8242; site is supported by partial inhibition of pseudovirus entry by cathepsin L inhibitors in TMPRSS2<sup>+</sup> cells<sup><xref ref-type="bibr" rid="CR138">138</xref>,<xref ref-type="bibr" rid="CR141">141</xref></sup>.</p><p id="Par39">Cathepsins are non-specific proteases with endopeptidase and exopeptidase activities that participate in protein degradation in the late endosomes and lysosomes. They are divided into three catalytic classes: aspartic (D and E), serine (G) and cysteine (B, C, K, L, S and V) proteases. Of these, cysteine proteases (cathepsins B, L and S) contribute the most to viral entry. The role of cathepsins in viral entry is derived mostly from studies on reoviruses, Ebola virus and SARS-CoV<sup><xref ref-type="bibr" rid="CR142">142</xref>&#8211;<xref ref-type="bibr" rid="CR144">144</xref></sup>, with limited reports on SARS-CoV-2 (ref.<sup><xref ref-type="bibr" rid="CR138">138</xref></sup>). Whereas&#160;cathepsin B plays an essential role in Ebola virus entry, cathepsin L plays a greater role in SARS-CoV<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR142">142</xref></sup> and SARS-CoV-2 (refs<sup><xref ref-type="bibr" rid="CR138">138</xref>,<xref ref-type="bibr" rid="CR141">141</xref></sup>) entry. The lower dependence of SARS-CoV-2 on the endosomal pathway explains the limited effect of endosomal acidification inhibitors such as hydroxychloroquine on restricting SARS-CoV-2 infection of target cells<sup><xref ref-type="bibr" rid="CR138">138</xref></sup>. In one study, while the potency of hydroxychloroquine was dramatically impaired when the target cell expressed TMPRSS2, it was partially restored in the presence of a TMPRSS2 inhibitor<sup><xref ref-type="bibr" rid="CR138">138</xref></sup>, suggesting a potential benefit of combined use of a TMPRSS2 inhibitor and hydroxychloroquine.</p></sec><sec id="Sec18"><title>Membrane fusion</title><p id="Par40">Recent structural studies identified key components of the S fusion machinery, including the FPPR, 630 loop and CTD2, which appear to modulate the fusogenic structural rearrangements of the S protein (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). The FPPR and the 630 loop help maintain the RBDs in the down conformation but move out of their positions when the adjacent RBD flips up. As summarized in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>, the RBD could sample the up conformation due to intrinsic protein dynamics. If ACE2 captures the RBD-up conformation, expelling both the 630 loop and the FPPR from their positions in the closed S trimer conformation, the FPPR shift may help expose the S2&#8242; site near the fusion peptide for proteolytic cleavage. Departure of the 630 loop from the hydrophobic surface of CTD2 can destabilize this domain and free the N-terminal segment of S2 from S1, likely releasing S1 altogether, owing to the precleavage of the S1&#8211;S2 boundary of the SARS-CoV-2 S protein by furin as discussed earlier. Dissociation of S1 would then initiate a cascade of refolding events in the metastable prefusion S2, allowing the fusogenic transition to a stable postfusion structure (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). Accompanying these transitions, the thrust of HR1 unfolding drives fusion peptide insertion into the target-cell membrane<sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup>. Folding back of HR2 places&#160;the fusion peptide and transmembrane segments at the same end of the molecule; this proximity causes the membranes with which they interact to bend towards each other, effectively leading to membrane fusion. This model is also very similar to that proposed for membrane fusion catalysed by the HIV envelope protein, in which gp120 dissociation triggers refolding of gp41 to complete the fusion process<sup><xref ref-type="bibr" rid="CR145">145</xref></sup>.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>A model for membrane fusion induced by the SARS-CoV-2 S protein.</title><p>Structural transition from the prefusion conformation to the postfusion conformation inducing membrane fusion likely proceeds stepwise as follows. The prefusion spike (S) protein trimer fluctuates between the three receptor-binding domain (RBD)-down, closed conformations and one RBD-up, open conformation. RBD binding to angiotensin-converting enzyme 2 (ACE2) enables exposure of the S2&#8242; cleavage site immediately upstream of the adjacent fusion peptide (FP). Cleavage at the S2&#8242; site releases the structural constraints on the FP and initiates a cascade of refolding events in S2, probably accompanied by complete dissociation of S1. Formation of the long central three-stranded coiled coil and folding back of heptad repeat 2 (HR2) leads to the postfusion structure of S2 that brings the two membranes together, facilitating fusion pore formation and viral entry. As shown in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>, these events can occur either at the plasma membrane or in the endosomal compartment. HR1, heptad repeat 1; TM, transmembrane segment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2044" position="float" orientation="portrait" xlink:href="41580_2021_418_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec19"><title>Cellular proteins restricting viral entry</title><p id="Par41">Toll-like receptors (TLRs) recognize pathogen-associated molecular patterns and induce the production of type I interferons. Of these, TLR3, TLR7, TLR8 and TLR9 mount antiviral immune responses: TLR3 recognizes double-stranded RNA viruses, TLR9 recognizes unmethylated CpG in viral DNA, and, relevant to coronaviruses, TLR7 and TLR8 bind G/U-rich single-stranded viral RNA. TLR7 and TLR8 reside in the endosomes and were shown to induce proinflammatory cytokines in response to SARS-CoV and SARS-CoV-2 RNA<sup><xref ref-type="bibr" rid="CR146">146</xref>,<xref ref-type="bibr" rid="CR147">147</xref></sup>. TLR7 and TLR8 are both expressed in lung tissue. Although TLR7 is expressed at higher levels in the brain, skin and lymphoid tissues than in the lung, TLR8 is predominantly expressed in the lung and lymphoid tissues.</p><p id="Par42">Many interferon-stimulated gene products were identified as important for SARS-CoV-2 replication, but only a few of them are involved in the entry steps: interferon-induced transmembrane proteins (IFITMs)<sup><xref ref-type="bibr" rid="CR148">148</xref>,<xref ref-type="bibr" rid="CR149">149</xref></sup> and lymphocyte antigen 6 family member E (LY6E)<sup><xref ref-type="bibr" rid="CR150">150</xref>,<xref ref-type="bibr" rid="CR151">151</xref></sup>. Four members of the human IFITM family (IFITM1, IFITM2, IFITM3 and IFITM5) are constitutively expressed at a high level but are strongly induced by type I and type II interferons and were identified as cellular antiviral proteins against influenza A viruses and flaviviruses<sup><xref ref-type="bibr" rid="CR152">152</xref></sup> and later against filoviruses and SARS-CoV<sup><xref ref-type="bibr" rid="CR153">153</xref></sup>. Recently, IFITM2 was shown to restrict SARS-CoV-2 entry<sup><xref ref-type="bibr" rid="CR149">149</xref></sup>. IFITM proteins prevent viruses from traversing the endosomal membrane to access cellular cytoplasm by an unclear mechanism. Such a restriction can be bypassed if SARS-CoV were directed to enter cells exclusively at the plasma membrane<sup><xref ref-type="bibr" rid="CR153">153</xref></sup>. This restriction is amplified if the furin site is removed from SARS-CoV-2 (ref.<sup><xref ref-type="bibr" rid="CR149">149</xref></sup>), and is compensated by TMPRSS2 overexpression<sup><xref ref-type="bibr" rid="CR148">148</xref>,<xref ref-type="bibr" rid="CR151">151</xref></sup>. In addition, it does not affect the&#160;viruses that enter the host cell solely via fusion at the plasma membrane<sup><xref ref-type="bibr" rid="CR153">153</xref></sup>. These observations indicate that the site of membrane fusion is crucial for the antiviral activity of IFITM proteins.</p><p id="Par43">LY6E is a glycophosphatidylinositol-anchored cell surface protein and was shown to inhibit replication of vesicular stomatitis virus and mouse hepatitis virus<sup><xref ref-type="bibr" rid="CR154">154</xref></sup>, but it was also identified to promote yellow fever virus replication<sup><xref ref-type="bibr" rid="CR155">155</xref></sup>, HIV-1 entry<sup><xref ref-type="bibr" rid="CR156">156</xref></sup>, flavivirus internalization<sup><xref ref-type="bibr" rid="CR157">157</xref></sup> and influenza A virus entry<sup><xref ref-type="bibr" rid="CR158">158</xref></sup>. Proposed mechanisms for entry enhancement include formation of a microtubule-like network that likely guides endocytosed viruses along the tubules<sup><xref ref-type="bibr" rid="CR157">157</xref></sup> and promotion of uncoating steps following membrane fusion<sup><xref ref-type="bibr" rid="CR158">158</xref></sup>. Recently, LY6E was shown to impair infection by SARS-CoV, SAR-CoV-2 and MERS-CoV by inhibiting the S protein-mediated membrane fusion, and mice lacking LY6E expression in immune cells were highly susceptible to mouse hepatitis virus, also a coronavirus<sup><xref ref-type="bibr" rid="CR150">150</xref></sup>. Unlike IFITM-mediated restriction, LY6E-mediated inhibition was not overcome by TMPRSS2 expression<sup><xref ref-type="bibr" rid="CR151">151</xref></sup>. Further study is warranted to clarify the distinct roles of LY6E in regulating infection with SARS-CoV-2 and other viruses.</p></sec></sec><sec id="Sec20"><title>Natural evolution of the S protein</title><p id="Par44">Comparison of the S protein sequences indicates SARS-CoV-2 may have emerged from the recombination between bat and pangolin coronaviruses. During zoonosis, SARS-CoV-2 acquired a furin-cleavage site at the boundary of the S1 and S2 domains. The virus retained this cleavage site throughout the pandemic but acquired the D614G mutation to compensate for S protein instability. More recently, as the number of infected or vaccinated people increases, SARS-CoV-2 has evolved to acquire S protein mutations to escape neutralizing antibodies.</p><sec id="Sec21"><title>S proteins from sarbecoviruses in reservoir species</title><p id="Par45">Specimens taken from pangolins (<italic toggle="yes">Manis javanica</italic>) were found to be infected with coronaviruses similar in sequence to SARS-CoV-2 and capable of utilizing ACE2 for entry<sup><xref ref-type="bibr" rid="CR100">100</xref>&#8211;<xref ref-type="bibr" rid="CR102">102</xref></sup>. However, the pangolin is not likely the long-term reservoir species for SARS-CoV-2, because most infected pangolins exhibited severe respiratory distress and died within weeks<sup><xref ref-type="bibr" rid="CR102">102</xref></sup>. In addition, because pangolin coronaviruses share lower sequence homology with SARS-CoV-2 than does RaTG13, a bat isolate, it is unlikely that a particular pangolin coronavirus is directly linked to the present SARS-CoV-2 outbreak. Interestingly, whereas pangolin isolates exhibit higher homology in the RBD with SARS-CoV-2 than does RaTG13, RaTG13 shares much greater homology with SARS-CoV-2 than do pangolin isolates outside the RBD<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR100">100</xref>,<xref ref-type="bibr" rid="CR102">102</xref></sup>. This raises a possibility that the pangolin coronavirus RBD was introduced into the S gene of RaTG13 or another close ancestor of SARS-CoV-2 through a recombination event<sup><xref ref-type="bibr" rid="CR104">104</xref>,<xref ref-type="bibr" rid="CR159">159</xref></sup>. It remains unknown in which species, if any, this recombination event occurred. Other analyses suggest SARS-CoV-2 did not acquire the RBD from a pangolin coronavirus but rather that it evolved in bats and gained the ability to infect humans and pangolins<sup><xref ref-type="bibr" rid="CR160">160</xref>,<xref ref-type="bibr" rid="CR161">161</xref></sup>. Furthermore, other studies suggest SARS-CoV-2 crept into humans much earlier than 2019 through unnoticed infection and obtained its unique features, RBD and furin-cleavage site<sup><xref ref-type="bibr" rid="CR160">160</xref>,<xref ref-type="bibr" rid="CR162">162</xref></sup>.</p></sec><sec id="Sec22"><title>Adaptation to humans</title><p id="Par46">It was suggested that the acquisition of the furin-cleavage site in the SARS-CoV-2 S protein was essential for zoonotic transfer to humans<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR163">163</xref></sup>, and experimental data confirmed that SARS-CoV-2 pseudoviruses lacking this cleavage site in the S protein are incapable of facilitating entry into human airway cells<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Notably, the furin site is not essential for infection of mammalian epithelial cells generally, as it is lost after a few passages of the virus in Vero cells (African green monkey kidney epithelial cells)<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR164">164</xref>&#8211;<xref ref-type="bibr" rid="CR167">167</xref></sup>. However, recent preliminary studies show virus passage in TMPRSS2-overexpressing Vero cells or in human lung cells prevents deletion or mutation of this site<sup><xref ref-type="bibr" rid="CR167">167</xref>&#8211;<xref ref-type="bibr" rid="CR169">169</xref></sup>. Therefore, acquisition of the furin-cleavage site appears to be one of the first human adaptation events.</p><p id="Par47">For several months as SARS-CoV-2 initially spread throughout the world, only one S protein mutation, D614G, exhibited clear evidence of positive selection<sup><xref ref-type="bibr" rid="CR170">170</xref>,<xref ref-type="bibr" rid="CR171">171</xref></sup>. Although acquisition of the furin site by SARS-CoV-2 and the resulting S protein cleavage appear to be essential for human infection, they also makes the virus less infectious than SARS-CoV by rendering the S protein prone to S1 shedding, as discussed earlier. To compensate for this disadvantage, the SARS-CoV-2 S protein appears to have gained stronger intermolecular association between the S1 and S2 subunits, by way of the D614G mutation. A number of studies have supported such a stabilizing effect as the mode of infectivity enhancement of the D614G variant virus<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR127">127</xref>,<xref ref-type="bibr" rid="CR172">172</xref>&#8211;<xref ref-type="bibr" rid="CR174">174</xref></sup>. Cryo-EM studies of full-length S trimers revealed the source of the increased S protein stability: the D614G mutation renders the 630 loop more ordered, securing the NTD and CTD1 and resulting in reduced S1 shedding<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup> (Fig.&#160;<xref rid="Fig2" ref-type="fig">2b</xref>,<xref rid="Fig2" ref-type="fig">c</xref>). A biochemical study clearly showed increased functional S protein density on the G614-containing variant as a result of reduced S1 shedding<sup><xref ref-type="bibr" rid="CR127">127</xref></sup>. Others have explained that a greater proportion of the one-RBD-up conformation among G614-containing S proteins is associated with increased virus infectivity<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR175">175</xref>&#8211;<xref ref-type="bibr" rid="CR177">177</xref></sup>. Most such studies, however, were performed with non-native S protein lacking the furin site and/or carrying the diproline mutation, which has been shown to stabilize the prefusion conformation<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Regardless of its mechanism for enhanced infectivity, faster transmission of D614G virus was demonstrated<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>. The fact that most currently circulating SARS-CoV-2 isolates carry the D614G mutation indicates it is undoubtedly a beneficial mutation for adaptation to humans.</p><p id="Par48">Additional adaptations to the human host are ongoing. The SARS-CoV-2 variants Alpha (lineage B.1.1.7), Beta (B.1.351) and Gamma (P.1), which were first identified in the United Kingdom, South Africa and Brazil, respectively, carry a common N501Y mutation in addition to the D614G mutation (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Residue 501 is one of the key sites within the RBD involved in ACE2 binding<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR178">178</xref>,<xref ref-type="bibr" rid="CR179">179</xref></sup>, and recent preliminary reports demonstrate that N501Y mutation strengthens RBD interaction with hACE2 (refs<sup><xref ref-type="bibr" rid="CR180">180</xref>,<xref ref-type="bibr" rid="CR181">181</xref></sup>) and increases the&#160;infectivity and virulence of variants containing the mutation<sup><xref ref-type="bibr" rid="CR182">182</xref>&#8211;<xref ref-type="bibr" rid="CR184">184</xref></sup>. Interestingly, data indicate that the N501Y substitution also lends the S protein the ability to utilize mouse and rat ACE2 orthologues<sup><xref ref-type="bibr" rid="CR182">182</xref>,<xref ref-type="bibr" rid="CR185">185</xref>,<xref ref-type="bibr" rid="CR186">186</xref></sup>, raising concern for the potential of new rodent reservoirs. A recent variant, Delta (B.1.617.2), first identified in India, does not have this N501Y mutation, but it nonetheless exhibits significantly increased transmissibility by an unknown mechanism<sup><xref ref-type="bibr" rid="CR187">187</xref></sup>. Increased cleavage at the S1&#8211;S2 boundary due to the P681R mutation in the furin-cleavage site might further contribute to increased transmissibility<sup><xref ref-type="bibr" rid="CR128">128</xref>,<xref ref-type="bibr" rid="CR188">188</xref></sup>.</p></sec><sec id="Sec23"><title>Immune escape</title><p id="Par49">Viruses escape immunity by mutating the residues recognized by neutralizing antibodies. As immune escape is necessary only in the presence of immune pressure, no escape variants appeared in the early days of the pandemic, with lower dissemination and in the absence of vaccination. In recent months, however, several neutralization-resistant variants have emerged. The aforementioned Alpha, Beta, Gamma and Delta variants and the Epsilon variant (B.1.429, California lineage) exhibit decreased sensitivity to neutralization by immune plasma derived from convalescent patients with COVID-19 or vaccinated individuals<sup><xref ref-type="bibr" rid="CR40">40</xref>&#8211;<xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR185">185</xref>,<xref ref-type="bibr" rid="CR189">189</xref>&#8211;<xref ref-type="bibr" rid="CR194">194</xref></sup>. The possibility that these recent variants emerged from the infection of previously infected or vaccinated individuals is supported by studies in which escape variants were experimentally generated&#160;in the presence of neutralizing antibodies, convalescent sera or sera derived from vaccinated individuals<sup><xref ref-type="bibr" rid="CR195">195</xref>&#8211;<xref ref-type="bibr" rid="CR198">198</xref></sup>. In these studies, the same mutations, including K417N, E484K and N501Y in the RBD, which are the hallmarks of the Alpha, Beta, and Gamma variants, were identified. These variants are also fully or partially resistant to the therapeutic monoclonal antibodies bamlanivimab (Eli Lilly) and/or casirivimab (Regeneron)<sup><xref ref-type="bibr" rid="CR178">178</xref>,<xref ref-type="bibr" rid="CR189">189</xref>,<xref ref-type="bibr" rid="CR197">197</xref></sup>. It is likely that other variants, Eta (B.1.525, United Kingdom), Iota (B.1.526, New York) and Kappa (B.1.617.1, India), are also less sensitive to neutralization, owing to the Glu484 mutation to either Lys or Gln (E484K/Q). The rapidly spreading Delta variant does not carry E484K/Q, but it does have the additional mutation L452R, which confers neutralization resistance<sup><xref ref-type="bibr" rid="CR199">199</xref></sup> and is also present in the Eta and Iota&#160;variants.</p></sec></sec><sec id="Sec24"><title>Conclusions and perspective</title><p id="Par50">Three zoonotic coronaviruses have emerged to cause severe disease in humans in the last two decades: SARS-CoV, MERS-CoV and SARS-CoV-2. The frequency of these zoonoses, accelerated by increased human intrusion into previously undisturbed habitats, suggests that new coronaviruses and other emerging pathogens will continue to threaten human health. Despite the warning signs from SARS-CoV and MERS-CoV outbreaks, few anticipated a pandemic of the scale that was caused by SARS-CoV-2. Fortunately, and owing in part to lessons learned from the previous outbreaks, our understanding of SARS-CoV-2 biology and the development of vaccines (Box&#160;<xref rid="Sec25" ref-type="sec">2</xref>; Table&#160;<xref rid="Tab2" ref-type="table">2</xref>) and therapeutics have proceeded at an unprecedented pace. In spite of these achievements, there remain many outstanding questions whose answers may assist in the development of new tools to control these viruses.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Selected products used in global vaccination campaigns</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Product</th><th colspan="1" rowspan="1">Developers</th><th colspan="1" rowspan="1">Platform</th><th colspan="1" rowspan="1">Antigen</th><th colspan="1" rowspan="1">First deployment</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">CoronaVac</td><td colspan="1" rowspan="1">Sinovac</td><td colspan="1" rowspan="1">Inactivated virus (alum adjuvant)</td><td colspan="1" rowspan="1">Whole virion, including WT S protein<sup>a</sup></td><td colspan="1" rowspan="1">29 Aug 2020 (China)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR217">217</xref></sup></td></tr><tr><td colspan="1" rowspan="1">BNT162b2 (Comirnaty)</td><td colspan="1" rowspan="1">Pfizer, BioNTech</td><td colspan="1" rowspan="1">mRNA&#8211;lipid nanoparticle</td><td colspan="1" rowspan="1">S protein (2P)<sup>b</sup></td><td colspan="1" rowspan="1">2 Dec 2020 (United Kingdom)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR218">218</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Gam-COVID-Vac (Sputnik V)</td><td colspan="1" rowspan="1">Gamaleya Research Institute, Health Ministry of the Russian Federation</td><td colspan="1" rowspan="1">Non-replicating adenoviral vectors rAd26 and rAd5</td><td colspan="1" rowspan="1">WT S protein<sup>a</sup></td><td colspan="1" rowspan="1">5 Dec 2020 (Russia)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR219">219</xref></sup></td></tr><tr><td colspan="1" rowspan="1">mRNA-1273</td><td colspan="1" rowspan="1">Moderna, US National Institute of Allergy and Infectious Diseases</td><td colspan="1" rowspan="1">mRNA&#8211;lipid nanoparticle</td><td colspan="1" rowspan="1">S protein (2P)<sup>b</sup></td><td colspan="1" rowspan="1">18 Dec 2020 (United States)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR220">220</xref></sup></td></tr><tr><td colspan="1" rowspan="1">AZD1222 (Covishield)</td><td colspan="1" rowspan="1">AstraZeneca, University of Oxford</td><td colspan="1" rowspan="1">Non-replicating adenoviral vector ChAdOx1</td><td colspan="1" rowspan="1">WT S protein<sup>a</sup></td><td colspan="1" rowspan="1">30 Dec 2020 (United Kingdom)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR221">221</xref></sup></td></tr><tr><td colspan="1" rowspan="1">BBV152 (Covaxin)</td><td colspan="1" rowspan="1">Bharat Biotech International</td><td colspan="1" rowspan="1">Inactivated virus (Algel-IMDG adjuvant)</td><td colspan="1" rowspan="1">Whole virion, including WT S protein<sup>a</sup></td><td colspan="1" rowspan="1">2 Jan 2021 (India)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR222">222</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Ad26.COV2.S</td><td colspan="1" rowspan="1">Janssen Pharmaceutical (Johnson &amp; Johnson)</td><td colspan="1" rowspan="1">Non-replicating adenoviral vector rAd26</td><td colspan="1" rowspan="1">S protein (FKO&#8201;+&#8201;2P)<sup>c</sup></td><td colspan="1" rowspan="1">17 Feb 2021 (South Africa)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR223">223</xref></sup></td></tr><tr><td colspan="1" rowspan="1">NVX-CoV2373</td><td colspan="1" rowspan="1">Novavax</td><td colspan="1" rowspan="1">Protein subunit&#8211;nanoparticle (Matrix M adjuvant)</td><td colspan="1" rowspan="1">S protein (FKO&#8201;+&#8201;2P)<sup>c</sup></td><td colspan="1" rowspan="1">Pending<sup>d</sup></td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR224">224</xref></sup></td></tr></tbody></table><table-wrap-foot><p>The vaccines that had received or are close to receiving emergency use authorization at the time of writing are included. S protein, spike protein; 2P, diproline mutation (K986P and V987P); FKO, furin-cleavage site knocked out; WT, wild type. <sup>a</sup>Full-length WT S protein. <sup>b</sup>Full-length S protein with 2P mutation in the S2 subunit to stabilize prefusion conformation. <sup>c</sup>Full-length S protein with FKO and 2P mutation added to stabilize prefusion conformation. <sup>d</sup>Application for emergency use authorization had been submitted in several countries as of August 2021 but had not been received at the time of writing.</p></table-wrap-foot></table-wrap></p><p id="Par51">One question is when in its natural history did the virus acquire a furin site? As already mentioned, cleavage of the SARS-CoV-2 S protein into the S1 and S2 subunits results in an unstable S protein. Nonetheless, the virus has judiciously held onto the furin site throughout the pandemic without deleting or mutating it. In addition, this furin site was shown to be important for transmission in ferrets<sup><xref ref-type="bibr" rid="CR128">128</xref></sup>. One logical explanation is that the cleavage of the ancestral sequence at the S1&#8211;S2 junction (the sequence before the virus acquired the furin site) by target-cell proteases such as TMPRSS2 might have been inefficient, and thus the virus opted to precleave the site at the cost of resulting S protein instability. On the other hand, studies show that SARS-CoV-2 is nonetheless more dependent on TMPRSS2 than on cathepsins<sup><xref ref-type="bibr" rid="CR138">138</xref></sup>. Recent studies on IFITM proteins, type I interferon-induced endosomal virus restriction factors, provide one clue to this puzzle. SARS-CoV-2 lacking the polybasic site is more sensitive to IFITM-mediated restriction than the wild-type virus<sup><xref ref-type="bibr" rid="CR128">128</xref>,<xref ref-type="bibr" rid="CR149">149</xref></sup>, suggesting the virus chose to use TMPRSS2 to enter cells to avoid IFITM-mediated restriction in the endosome. Alternatively, this preference of SARS-CoV-2 for TMPRSS2 can also be explained if tight folding of the SARS-CoV S protein allows the precise exposure of the S2&#8242; site to cathepsin L, a protease with low substrate specificity, while the difference in SARS-CoV-2 S protein folding may not confine cathepsin digestion to only the S2&#8242; site, leading to overdigestion of the neighbouring sequences, which renders the fusion peptide non-functional. These situations would force SARS-CoV-2 to prefer TMPRSS2 to cathepsins. If so, the furin dependency and TMPRSS2 dependency of SARS-CoV-2 appear to reflect a choice of less bad options. Of these, S protein instability was compensated by acquisition of the D614G mutation<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR127">127</xref></sup>. If TMPRSS2 inhibitors become widely used, it is possible the virus will acquire mutations that facilitate escape from inhibitory action of IFITM proteins and enable more precise use of cathepsins, suggesting the benefit of use of combinatorial therapies targeting both pathways (camostat mesylate plus hydroxychloroquine).</p><p id="Par52">Some critical questions are associated with the link between transmissibility and disease severity. As a virus better adapts in a species, the severity of the disease can diminish, but recent changes in SARS-CoV-2 have increased both transmissibility and hospitalizations. A&#160;positive relationship between transmissibility and hospitalizations may reflect a common underlying mechanism: higher affinity for ACE2 can increase both. More efficient binding to ACE2 can promote replication in the upper respiratory tract, promoting more efficient transmission, and it can also increase replication in the lower respiratory tract and systemically, causing severer disease. One outstanding question is whether the S&#160;protein has reached the maximum affinity for hACE2 through RBD mutations such as N501Y or whether it will further mutate and continue to enhance both transmissibility and pathogenicity. Or might countervailing selection pressures result in transmission gains but with milder disease? If the differences between the upper and lower respiratory tracts allow the virus to adapt specifically to, say, nasal epithelial cells, the link between transmission and disease severity may be broken.</p><p id="Par53">At the time of writing, the pandemic appears to be shifting gears, moving from an early period of adaptation of the virus to its new human host to a longer period where immune escape will shape S protein evolution. A key question here is what future vaccine antigens should look like. The S protein is rapidly diversifying, and current vaccination strategies (Box&#160;<xref rid="Sec25" ref-type="sec">2</xref>; Table&#160;<xref rid="Tab2" ref-type="table">2</xref>) may soon become impractical, necessitating vaccine deployment against every major circulating variant. The major antibody-neutralizing epitope of the S protein is the RBD, accounting for more than 90% of all&#160;neutralizing activity, although the NTD also has some neutralizing epitopes. Importantly, the NTD is changing faster, acquiring more mutations and deletions than the RBD; understandably because the NTD plays at most a secondary role in viral entry and thus is subject to fewer constraints on its evolution. The remainder of the S protein, including the S2 subunit, does not appear to elicit significant neutralizing responses. Therefore, RBD vaccines presenting multiple RBDs derived from various escape variants may make superior antigens for future vaccines.</p><p id="Par54">A related question is whether the accessible pathways of viral escape are essentially unlimited, or whether they are constrained, especially in the RBD, so that only a tractable number of mutations are likely to emerge. If the latter is true, they might be anticipated and blocked pre-emptively. So far, four major regions or residues in the S1 subunit have been identified that render the virus less sensitive to immune sera: a supersite in the NTD (residues 14&#8211;26, 141&#8211;156 and 246&#8211;260)<sup><xref ref-type="bibr" rid="CR200">200</xref>&#8211;<xref ref-type="bibr" rid="CR203">203</xref></sup> and residues 417, 484 and 501 in the RBD<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR200">200</xref>,<xref ref-type="bibr" rid="CR204">204</xref></sup>. Interestingly, the immune-escape mutations selected in several in vitro studies overlap with those that naturally emerged from human infection<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR191">191</xref>,<xref ref-type="bibr" rid="CR202">202</xref>,<xref ref-type="bibr" rid="CR205">205</xref></sup> and those selected in the presence of monoclonal antibodies or sera derived from infected or vaccinated individuals<sup><xref ref-type="bibr" rid="CR195">195</xref>&#8211;<xref ref-type="bibr" rid="CR197">197</xref></sup>. These observations imply that there might indeed be only a limited number of escape pathways the virus can take and that those pathways could be blocked. Alternatively, the mutations the virus has been accumulating so far could represent the first &#8216;low-hanging fruit&#8217; available to the virus. Indeed, all major mutations in the RBD to date have been accessed through a single nucleotide change, and so, in the pessimistic scenario, the virus could further evolve through more complex mutations such as several synergistic or compensatory mutations in parallel. Moreover, several recent mutations have increased RBD affinity for ACE2 (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Unfortunately, this adaptation provides the virus with some breathing room to accommodate immune-escape mutations that will likely decrease the affinity for ACE2.</p><p id="Par55">Thus, unfortunately, SARS-CoV-2 variants may continue to adapt in the human population for years or decades. This raises additional questions. As coronaviruses are especially good at recombining with other coronaviruses<sup><xref ref-type="bibr" rid="CR206">206</xref></sup>, will a recombination event with one of the milder coronaviruses that regularly circulate among humans generate an entirely new virus? Will SARS-CoV-2 diversify into even more distinct lineages more akin to the many forms of influenza A viruses with which we regularly contend? Will SARS-CoV-2 stably remain among our livestock or pests, perhaps creating reservoirs for new zoonoses? Perhaps the most critical question is whether we can finally learn the clearest lesson of the COVID-19 pandemic; namely, can we fully appreciate that viral infections are a major threat to all of us, but at the same time are fully addressable with our current technologies and effective implementation of well-established public health principles? If we learn this lesson well, hopefully this will be our last pandemic.</p><sec id="Sec25"><boxed-text position="float" orientation="portrait"><label>Box 2 Vaccines against SARS-CoV-2</label><p id="Par56">Vaccine products against SARS-CoV-2 based on several technology platforms (see the figure) have been advanced to clinical trials and emergency use worldwide (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). In a conventional approach, inactivated whole-virus vaccine (far left in the figure) is generated by inactivating purified SARS-CoV-2 with formaldehyde and mixing it with an <xref rid="Glos21" ref-type="list">adjuvant</xref> such as alum (CoronaVac) or Algel-IMDG (BBV152)<sup><xref ref-type="bibr" rid="CR217">217</xref>,<xref ref-type="bibr" rid="CR222">222</xref></sup>. Whereas the spike (S) protein is the sole source of T cell epitopes in most other popular SARS-CoV-2 vaccines, whole-virus vaccine provides a wide repertoire of T cell epitopes in other viral proteins. The disadvantages, however, include lower immunogenicity owing to the perturbation of the antigen structure by the fixation process, production difficulties and residual risks, albeit minor, associated with incomplete inactivation of the virus.</p><p id="Par57">The protein subunit&#8211;nanoparticle vaccine (middle left in the figure) is produced by incorporation of purified recombinant S protein into <xref rid="Glos22" ref-type="list">polysorbate 80</xref> micelles with the addition of the saponin-based adjuvant Matrix-M (NVX-CoV2373)<sup><xref ref-type="bibr" rid="CR224">224</xref></sup>. Preliminary trial results for NVX-CoV2373 demonstrate robust humoral and cell-mediated immunity, although the induction of the latter by Matrix-M is not yet completely understood<sup><xref ref-type="bibr" rid="CR260">260</xref></sup>.</p><p id="Par58">Two vaccine platforms using gene therapy technologies to elicit production of the S protein antigen in host cells have also proven effective and have exceptional intrinsic immunogenicity. These are non-replicating recombinant adenoviral vector systems (middle right in the figure), which carry the gene encoding the S protein (Gam-COVID-Vac, AZD1222 and Ad26.COV2.S)<sup><xref ref-type="bibr" rid="CR219">219</xref>,<xref ref-type="bibr" rid="CR221">221</xref>,<xref ref-type="bibr" rid="CR223">223</xref></sup> and mRNA&#8211;LNP (lipid nanoparticle) systems (far right in the figure), wherein chemically modified mRNA encoding the S protein bound to ionizable lipids is encapsulated inside a layer of mixed lipids (BNT162b2 and mRNA-1273)<sup><xref ref-type="bibr" rid="CR218">218</xref>,<xref ref-type="bibr" rid="CR220">220</xref></sup>. The response to the COVID-19 pandemic has highlighted distinct advantages of the mRNA&#8211;LNP technology in rapid prototyping and manufacturing on a large scale<sup><xref ref-type="bibr" rid="CR261">261</xref></sup>.</p><p id="Par59">All current vaccines are based on the S protein sequence of the Wuhan-Hu-1 strain predating the D614G mutation, which stabilizes the S protein<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR127">127</xref>,<xref ref-type="bibr" rid="CR171">171</xref>,<xref ref-type="bibr" rid="CR174">174</xref></sup> and is present in all currently circulating variants (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). To stabilize the S protein, some vaccine designs incorporated furin-site knockout and/or diproline mutations in the S protein. &#8216;Diproline mutation&#8217; refers to the mutation of two consecutive residues in the S2 subunit (Lys986 and Val987) to proline and used to stabilize prefusion conformation of the S protein<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Other vaccines, such as AZD1222 and the inactivated whole-virus vaccines, utilize the unmodified S protein<sup><xref ref-type="bibr" rid="CR217">217</xref>,<xref ref-type="bibr" rid="CR221">221</xref>,<xref ref-type="bibr" rid="CR222">222</xref></sup> (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Therefore, differences in vaccine efficacy may be due to not only their differing vectors and formulations but also the particular S protein construct used.<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d32e2805" orientation="portrait" xlink:href="41580_2021_418_Figa_HTML.jpg"/></p></boxed-text></sec></sec></body><back><fn-group><fn><p><bold>Peer review information</bold></p><p><italic toggle="yes">Nature Reviews Molecular Cell Biology</italic> thanks A. Helenius, Y. Yamauchi and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.</p></fn><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by an administrative supplement to NIH grant R01 AI129868 for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) research to M.F. and H.C., a Fast grant by Emergent Ventures to B.C., a COVID-19 Award by the Massachusetts Consortium on Pathogen Readiness to B.C. and an administrative supplement to NIH grant AI147884 to B.C.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>C.B.J., B.C. and H.C. researched data for the article. All authors contributed substantially to discussion of the content and wrote the article. C.B.J. and H.C. reviewed and edited the manuscript before submission.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par60">The authors declare no competing interests.</p></notes><glossary><title>Glossary</title><def-list><def-item id="Glos1"><term>Angiotensin-converting enzyme 2</term><def><p>(ACE2). A zinc metalloproteinase that cleaves angiotensin I and angiotensin II into angiotensin-(1&#8211;9) and angiotensin-(1&#8211;7) as well as other peptide substrates, countering vasoconstriction mediated by angiotensin-converting enzyme (ACE). It also serves as the primary receptor for severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2 and other sarbecoviruses.</p></def></def-item><def-item id="Glos2"><term>Proprotein convertases</term><def><p>A family of membrane-associated or secreted serine proteases involved in activating proproteins, including prohormones, by removing the blocking portion of the protein.</p></def></def-item><def-item id="Glos3"><term>Furin</term><def><p>A proprotein convertase family transmembrane protein that resides in the Golgi apparatus. It recognizes and cleaves the polybasic motifs of various viral entry glycoproteins, including those of HIV-1, avian influenza A virus and severe acute respiratory syndrome coronavirus 2.</p></def></def-item><def-item id="Glos4"><term>Fusion peptide</term><def><p>A hydrophobic peptide of 20&#8211;25 residues that mediates fusion between viral and cellular membranes. The viral entry process requires appropriately timed exposure of this peptide, typically achieved through proteolysis and conformational changes in the entry glycoprotein after receptor binding.</p></def></def-item><def-item id="Glos5"><term>Transmembrane protease, serine 2</term><def><p>(TMPRSS2). A transmembrane serine protein with broad specificity and multiple potential cellular substrates. It is frequently utilized by respiratory viruses, including severe acute respiratory syndrome coronavirus 2, to activate their entry glycoproteins.</p></def></def-item><def-item id="Glos6"><term>Cathepsin L</term><def><p>A soluble cysteine proteinase involved in protein degradation and antigen processing in the late endosomes and lysosomes. Several viruses, including Ebola virus and severe acute respiratory syndrome coronavirus, utilize this enzyme to activate their entry glycoproteins.</p></def></def-item><def-item id="Glos7"><term>Pseudoviruses</term><def><p>Laboratory tools used to study and compare viral entry processes and their inhibition. Pseudovirus particles are formed by the structural proteins of safe, non-replicative forms of viruses coated (pseudotyped) with the entry glycoprotein of a heterologous virus.</p></def></def-item><def-item id="Glos8"><term>Virus-like particles</term><def><p>Molecules similar to pseudoviruses in that they are replication incompetent but that, unlike psuedoviruses, are composed of structural proteins of the virus under study. They thus have properties (size, shape and budding site) more similar to those of the viruses from which the structural proteins are derived and can be used to study viral assembly.</p></def></def-item><def-item id="Glos9"><term>Type I membrane protein</term><def><p>A membrane protein that contains a single transmembrane domain oriented so that its amino terminus is on the extracellular/lumenal side. Synthesis of these proteins is initiated with a signal peptide that is removed in the endoplasmic reticulum.</p></def></def-item><def-item id="Glos10"><term>Sarbecoviruses</term><def><p>Coronaviruses that are related to severe acute respiratory syndrome coronavirus and belong to the subgenus Sarbecovirus in the genus Betacoronavirus. They are enveloped, positive-sense, single-stranded RNA viruses, usually use angiotensin-converting enzyme 2 as the entry receptor and infect humans, bats and other mammals.</p></def></def-item><def-item id="Glos11"><term>Angiotensin-converting enzyme</term><def><p>(ACE). Like ACE2, ACE is a metalloproteinase that requires zinc as a cofactor for its protease activity. It plays an essential role in regulating blood pressure by converting inactive angiotensin I to active angiotensin II.</p></def></def-item><def-item id="Glos12"><term>Collectrin</term><def><p>A transmembrane protein that regulates amino acid transporters in the kidney by enhancing their expression on the plasma membrane. Angiotensin-converting enzyme 2, through its homologous collectrin domain, binds and regulates the amino acid transporter B0AT1 (also known as SCL6A19).</p></def></def-item><def-item id="Glos13"><term>Renin&#8211;angiotensin&#8211;aldosterone system</term><def><p>A hormone system designed to regulate body fluid balance and thus blood pressure. Angiotensin-converting enzyme and angiotensin-converting enzyme 2, together with renin, angiotensin and aldosterone, regulate this system.</p></def></def-item><def-item id="Glos14"><term>Type II alveolar cells</term><def><p>Thin alveolar cells (pneumocytes) that produce pulmonary surfactant and that prevent lung collapse during breathing and keep the alveolar space free of liquid. They express angiotensin-converting enzyme 2 and transmembrane protease, serine 2 and are susceptible to infection by severe acute respiratory syndrome coronavirus 2.</p></def></def-item><def-item id="Glos15"><term>Ciliated cells</term><def><p>A cell type in the epithelium characterized by the presence of hair-like cilia on the apical side, which functions to clear foreign particles. Together with goblet cells, airway ciliated cells form an epithelial barrier.</p></def></def-item><def-item id="Glos16"><term>Chronic obstructive pulmonary disease</term><def><p>A chronic inflammatory lung disease characterized by inflammation of the bronchial lining (bronchitis) and/or damaged alveoli (emphysema). Typically caused by long-term exposure to irritating particles or gases, often cigarette smoke.</p></def></def-item><def-item id="Glos17"><term>Lectins</term><def><p>A family of proteins that bind various carbohydrate moieties and are often used by viruses to attach to the target cell surface.</p></def></def-item><def-item id="Glos18"><term>Neuropilin 1</term><def><p>(NRP1). A cell surface receptor involved in angiogenesis and formation of the neural circuit that binds many ligands and various coreceptors. It binds the polybasic furin-cleavage site of the S1 subunit and can promote infection by severe acute respiratory syndrome coronavirus 2.</p></def></def-item><def-item id="Glos19"><term>Goblet cells</term><def><p>A cell type in the respiratory and gastrointestinal epithelium. Airway goblet cells are characterized by mucus secretion forming a protective mucus layer and in general are not susceptible to infection by severe acute respiratory syndrome coronavirus 2.</p></def></def-item><def-item id="Glos20"><term>Type II transmembrane protein</term><def><p>A membrane protein that contains a single transmembrane segment with its amino terminus on the cytoplasmic side and its carboxy terminus on the extracellular/lumenal side of the membrane.</p></def></def-item><def-item id="Glos21"><term>Adjuvant</term><def><p>A substance that increases the potency or efficacy of a drug or boosts immune responses in vaccines.</p></def></def-item><def-item id="Glos22"><term>Polysorbate 80</term><def><p>A synthetic compound (marketed, for example, as Tween 80) that is often used as an emulsifier or defoamer in foods and medicines. In vaccines, it is used as a stabilizer.</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">32007145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmcid">PMC7159086</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Structural basis of receptor recognition by SARS-CoV-2</article-title><source>Nature</source><year>2020</year><volume>581</volume><fpage>221</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">32225175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2179-y</pub-id><pub-id pub-id-type="pmcid">PMC7328981</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P</given-names></name><etal/></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmid">32155444</pub-id><pub-id pub-id-type="pmcid">PMC7102599</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title><source>Nature</source><year>2020</year><volume>581</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">32225176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2180-5</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Structural and functional basis of SARS-CoV-2 entry by using human ACE2</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>894</fpage><lpage>904</lpage><pub-id pub-id-type="pmid">32275855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.03.045</pub-id><pub-id pub-id-type="pmcid">PMC7144619</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title><source>Nature</source><year>2003</year><volume>426</volume><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">14647384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature02145</pub-id><pub-id pub-id-type="pmcid">PMC7095016</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hofmann</surname><given-names>H</given-names></name><etal/></person-group><article-title>Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>7988</fpage><lpage>7993</lpage><pub-id pub-id-type="pmid">15897467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0409465102</pub-id><pub-id pub-id-type="pmcid">PMC1142358</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Kleine-Weber</surname><given-names>H</given-names></name><name name-style="western"><surname>P&#246;hlmann</surname><given-names>S</given-names></name></person-group><article-title>A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells</article-title><source>Mol. Cell</source><year>2020</year><volume>78</volume><fpage>779</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">32362314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2020.04.022</pub-id><pub-id pub-id-type="pmcid">PMC7194065</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cell entry mechanisms of SARS-CoV-2</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>11727</fpage><lpage>11734</lpage><pub-id pub-id-type="pmid">32376634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2003138117</pub-id><pub-id pub-id-type="pmcid">PMC7260975</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fehr</surname><given-names>AR</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Coronaviruses: an overview of their replication and pathogenesis</article-title><source>Methods Mol. Biol.</source><year>2015</year><volume>1282</volume><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">25720466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-2438-7_1</pub-id><pub-id pub-id-type="pmcid">PMC4369385</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glowacka</surname><given-names>I</given-names></name><etal/></person-group><article-title>Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>4122</fpage><lpage>4134</lpage><pub-id pub-id-type="pmid">21325420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02232-10</pub-id><pub-id pub-id-type="pmcid">PMC3126222</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuyama</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>12658</fpage><lpage>12664</lpage><pub-id pub-id-type="pmid">20926566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01542-10</pub-id><pub-id pub-id-type="pmcid">PMC3004351</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shulla</surname><given-names>A</given-names></name><etal/></person-group><article-title>A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>873</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">21068237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02062-10</pub-id><pub-id pub-id-type="pmcid">PMC3020023</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>IC</given-names></name><etal/></person-group><article-title>SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>3198</fpage><lpage>3203</lpage><pub-id pub-id-type="pmid">16339146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M508381200</pub-id><pub-id pub-id-type="pmcid">PMC8010168</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simmons</surname><given-names>G</given-names></name><etal/></person-group><article-title>Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>11876</fpage><lpage>11881</lpage><pub-id pub-id-type="pmid">16081529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0505577102</pub-id><pub-id pub-id-type="pmcid">PMC1188015</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayati</surname><given-names>A</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R</given-names></name><name name-style="western"><surname>Francis</surname><given-names>V</given-names></name><name name-style="western"><surname>McPherson</surname><given-names>PS</given-names></name></person-group><article-title>SARS-CoV-2 infects cells following viral entry via clathrin-mediated endocytosis</article-title><source>J. Biol. Chem.</source><year>2021</year><pub-id pub-id-type="doi">10.1016/j.jbc.2021.100306</pub-id><pub-id pub-id-type="pmid">33476648</pub-id><pub-id pub-id-type="pmcid">PMC7816624</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>8722</fpage><lpage>8729</lpage><pub-id pub-id-type="pmid">17522231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00253-07</pub-id><pub-id pub-id-type="pmcid">PMC1951348</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Allen</surname><given-names>JD</given-names></name><name name-style="western"><surname>Wrapp</surname><given-names>D</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>JS</given-names></name><name name-style="western"><surname>Crispin</surname><given-names>M</given-names></name></person-group><article-title>Site-specific glycan analysis of the SARS-CoV-2 spike</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>330</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">32366695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb9983</pub-id><pub-id pub-id-type="pmcid">PMC7199903</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>SC</given-names></name></person-group><article-title>Viral membrane fusion</article-title><source>Virology</source><year>2015</year><volume>479&#8211;480</volume><fpage>498</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">25866377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2015.03.043</pub-id><pub-id pub-id-type="pmcid">PMC4424100</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wrapp</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">32075877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmcid">PMC7164637</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gobeil</surname><given-names>SM</given-names></name><etal/></person-group><article-title>D614G mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1/S2 junction</article-title><source>Cell Rep.</source><year>2021</year><volume>34</volume><fpage>108630</fpage><pub-id pub-id-type="pmid">33417835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2020.108630</pub-id><pub-id pub-id-type="pmcid">PMC7762703</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>R</given-names></name><etal/></person-group><article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1444</fpage><lpage>1448</lpage><pub-id pub-id-type="pmid">32132184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb2762</pub-id><pub-id pub-id-type="pmcid">PMC7164635</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><etal/></person-group><article-title>Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion</article-title><source>Cell Res.</source><year>2020</year><volume>30</volume><fpage>343</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">32231345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-020-0305-x</pub-id><pub-id pub-id-type="pmcid">PMC7104723</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Distinct conformational states of SARS-CoV-2 spike protein</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>1586</fpage><lpage>1592</lpage><pub-id pub-id-type="pmid">32694201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd4251</pub-id><pub-id pub-id-type="pmcid">PMC7464562</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bangaru</surname><given-names>S</given-names></name><etal/></person-group><article-title>Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>1089</fpage><lpage>1094</lpage><pub-id pub-id-type="pmid">33082295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abe1502</pub-id><pub-id pub-id-type="pmcid">PMC7857404</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Structural impact on SARS-CoV-2 spike protein by D614G substitution</article-title><source>Science</source><year>2021</year><volume>372</volume><fpage>525</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">33727252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abf2303</pub-id><pub-id pub-id-type="pmcid">PMC8139424</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turonova</surname><given-names>B</given-names></name><etal/></person-group><article-title>In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">32817270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd5223</pub-id><pub-id pub-id-type="pmcid">PMC7665311</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ke</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Structures and distributions of SARS-CoV-2 spike proteins on intact virions</article-title><source>Nature</source><year>2020</year><volume>588</volume><fpage>498</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">32805734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2665-2</pub-id><pub-id pub-id-type="pmcid">PMC7116492</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>H</given-names></name><etal/></person-group><article-title>Molecular architecture of the SARS-CoV-2 virus</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>730</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">32979942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.09.018</pub-id><pub-id pub-id-type="pmcid">PMC7474903</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><etal/></person-group><article-title>The architecture of inactivated SARS-CoV-2 with postfusion spikes revealed by cryo-EM and cryo-ET</article-title><source>Structure</source><year>2020</year><volume>28</volume><fpage>1218</fpage><lpage>1224</lpage><pub-id pub-id-type="pmid">33058760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.str.2020.10.001</pub-id><pub-id pub-id-type="pmcid">PMC7557167</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunkel</surname><given-names>F</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>G</given-names></name></person-group><article-title>Structural and functional analysis of the surface protein of human coronavirus OC43</article-title><source>Virology</source><year>1993</year><volume>195</volume><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">8317096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/viro.1993.1360</pub-id><pub-id pub-id-type="pmcid">PMC7130786</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schultze</surname><given-names>B</given-names></name><name name-style="western"><surname>Gross</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Brossmer</surname><given-names>R</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>G</given-names></name></person-group><article-title>The S protein of bovine coronavirus is a hemagglutinin recognizing 9-O-acetylated sialic acid as a receptor determinant</article-title><source>J. Virol.</source><year>1991</year><volume>65</volume><fpage>6232</fpage><lpage>6237</lpage><pub-id pub-id-type="pmid">1920630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.65.11.6232-6237.1991</pub-id><pub-id pub-id-type="pmcid">PMC250319</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krempl</surname><given-names>C</given-names></name><name name-style="western"><surname>Schultze</surname><given-names>B</given-names></name><name name-style="western"><surname>Laude</surname><given-names>H</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>G</given-names></name></person-group><article-title>Point mutations in the S protein connect the sialic acid binding activity with the enteropathogenicity of transmissible gastroenteritis coronavirus</article-title><source>J. Virol.</source><year>1997</year><volume>71</volume><fpage>3285</fpage><lpage>3287</lpage><pub-id pub-id-type="pmid">9060696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.71.4.3285-3287.1997</pub-id><pub-id pub-id-type="pmcid">PMC191465</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><etal/></person-group><article-title>Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>3068</fpage><pub-id pub-id-type="pmid">31296843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-10897-4</pub-id><pub-id pub-id-type="pmcid">PMC6624210</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chi</surname><given-names>X</given-names></name><etal/></person-group><article-title>A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>650</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">32571838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc6952</pub-id><pub-id pub-id-type="pmcid">PMC7319273</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike</article-title><source>Nature</source><year>2020</year><volume>584</volume><fpage>450</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">32698192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2571-7</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wibmer</surname><given-names>CK</given-names></name><etal/></person-group><article-title>SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>622</fpage><lpage>625</lpage><pub-id pub-id-type="pmid">33654292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01285-x</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Serum neutralizing activity elicited by mRNA-1273 vaccine</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>1468</fpage><lpage>1470</lpage><pub-id pub-id-type="pmid">33730471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2102179</pub-id><pub-id pub-id-type="pmcid">PMC8008744</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants</article-title><source>Nature</source><year>2021</year><pub-id pub-id-type="doi">10.1038/s41586-021-03324-6</pub-id><pub-id pub-id-type="pmid">33567448</pub-id><pub-id pub-id-type="pmcid">PMC8503938</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><etal/></person-group><article-title>Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7</article-title><source>Nature</source><year>2021</year><pub-id pub-id-type="doi">10.1038/s41586-021-03398-2</pub-id><pub-id pub-id-type="pmid">33684923</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edara</surname><given-names>VV</given-names></name><etal/></person-group><article-title>Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants</article-title><source>N. Engl. J. Med.</source><year>2021</year><pub-id pub-id-type="doi">10.1056/NEJMc2107799</pub-id><pub-id pub-id-type="pmid">34233096</pub-id><pub-id pub-id-type="pmcid">PMC8279090</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wall</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>2331</fpage><lpage>2333</lpage><pub-id pub-id-type="pmid">34090624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01290-3</pub-id><pub-id pub-id-type="pmcid">PMC8175044</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Planas</surname><given-names>D</given-names></name><etal/></person-group><article-title>Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization</article-title><source>Nature</source><year>2021</year><pub-id pub-id-type="doi">10.1038/s41586-021-03777-9</pub-id><pub-id pub-id-type="pmid">34237773</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheikh</surname><given-names>A</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>2461</fpage><lpage>2462</lpage><pub-id pub-id-type="pmid">34139198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01358-1</pub-id><pub-id pub-id-type="pmcid">PMC8201647</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grabowski</surname><given-names>F</given-names></name><name name-style="western"><surname>Preibisch</surname><given-names>G</given-names></name><name name-style="western"><surname>Gizinski</surname><given-names>S</given-names></name><name name-style="western"><surname>Kochanczyk</surname><given-names>M</given-names></name><name name-style="western"><surname>Lipniacki</surname><given-names>T</given-names></name></person-group><article-title>SARS-CoV-2 variant of concern 202012/01 has about twofold replicative advantage and acquires concerning mutations</article-title><source>Viruses</source><year>2021</year><pub-id pub-id-type="doi">10.3390/v13030392</pub-id><pub-id pub-id-type="pmid">33804556</pub-id><pub-id pub-id-type="pmcid">PMC8000749</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tegally</surname><given-names>H</given-names></name><etal/></person-group><article-title>Detection of a SARS-CoV-2 variant of concern in South Africa</article-title><source>Nature</source><year>2021</year><volume>592</volume><fpage>438</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">33690265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03402-9</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voloch</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil</article-title><source>J. Virol.</source><year>2021</year><pub-id pub-id-type="doi">10.1128/JVI.00119-21</pub-id><pub-id pub-id-type="pmid">33649194</pub-id><pub-id pub-id-type="pmcid">PMC8139668</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tada</surname><given-names>T</given-names></name><etal/></person-group><article-title>SARS-CoV-2 lambda variant remains susceptible to neutralization by mRNA vaccine-elicited antibodies and convalescent serum</article-title><source>bioRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.07.02.450959</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>SC</given-names></name></person-group><article-title>Structure of SARS coronavirus spike receptor-binding domain complexed with receptor</article-title><source>Science</source><year>2005</year><volume>309</volume><fpage>1864</fpage><lpage>1868</lpage><pub-id pub-id-type="pmid">16166518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1116480</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wells</surname><given-names>HL</given-names></name><etal/></person-group><article-title>The evolutionary history of ACE2 usage within the coronavirus subgenus Sarbecovirus</article-title><source>Virus Evol.</source><year>2021</year><volume>7</volume><fpage>veab007</fpage><pub-id pub-id-type="pmid">33754082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ve/veab007</pub-id><pub-id pub-id-type="pmcid">PMC7928622</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>P</given-names></name><etal/></person-group><article-title>Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike</article-title><source>Cell</source><year>2021</year><pub-id pub-id-type="doi">10.1016/j.cell.2021.07.025</pub-id><pub-id pub-id-type="pmid">34332650</pub-id><pub-id pub-id-type="pmcid">PMC8299219</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>1010</fpage><lpage>1014</lpage><pub-id pub-id-type="pmid">32540901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd0827</pub-id><pub-id pub-id-type="pmcid">PMC7299284</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robbiani</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Convergent antibody responses to SARS-CoV-2 in convalescent individuals</article-title><source>Nature</source><year>2020</year><volume>584</volume><fpage>437</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">32555388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2456-9</pub-id><pub-id pub-id-type="pmcid">PMC7442695</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinto</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody</article-title><source>Nature</source><year>2020</year><volume>583</volume><fpage>290</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">32422645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2349-y</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>M</given-names></name><etal/></person-group><article-title>A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>630</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">32245784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb7269</pub-id><pub-id pub-id-type="pmcid">PMC7164391</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>11157</fpage><lpage>11162</lpage><pub-id pub-id-type="pmid">29073020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1708727114</pub-id><pub-id pub-id-type="pmcid">PMC5651768</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>X</given-names></name><name name-style="western"><surname>Cao</surname><given-names>D</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>3618</fpage><pub-id pub-id-type="pmid">32681106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-17371-6</pub-id><pub-id pub-id-type="pmcid">PMC7367865</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Hooper</surname><given-names>NM</given-names></name></person-group><article-title>The angiotensin-converting enzyme gene family: genomics and pharmacology</article-title><source>Trends Pharmacol. Sci.</source><year>2002</year><volume>23</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">11931993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0165-6147(00)01994-5</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donoghue</surname><given-names>M</given-names></name><etal/></person-group><article-title>A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1&#8211;9</article-title><source>Circ. Res.</source><year>2000</year><volume>87</volume><fpage>E1</fpage><lpage>E9</lpage><pub-id pub-id-type="pmid">10969042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.res.87.5.e1</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crackower</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Angiotensin-converting enzyme 2 is an essential regulator of heart function</article-title><source>Nature</source><year>2002</year><volume>417</volume><fpage>822</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">12075344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature00786</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tipnis</surname><given-names>SR</given-names></name><etal/></person-group><article-title>A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>33238</fpage><lpage>33243</lpage><pub-id pub-id-type="pmid">10924499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M002615200</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>G</given-names></name><etal/></person-group><article-title>Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26</article-title><source>Nature</source><year>2013</year><volume>500</volume><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">23831647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12328</pub-id><pub-id pub-id-type="pmcid">PMC7095341</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeager</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Human aminopeptidase N is a receptor for human coronavirus 229E</article-title><source>Nature</source><year>1992</year><volume>357</volume><fpage>420</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">1350662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/357420a0</pub-id><pub-id pub-id-type="pmcid">PMC7095410</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>VS</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title><source>Nature</source><year>2013</year><volume>495</volume><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">23486063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12005</pub-id><pub-id pub-id-type="pmcid">PMC7095326</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2</article-title><source>EMBO J.</source><year>2005</year><volume>24</volume><fpage>1634</fpage><lpage>1643</lpage><pub-id pub-id-type="pmid">15791205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.emboj.7600640</pub-id><pub-id pub-id-type="pmcid">PMC1142572</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuba</surname><given-names>K</given-names></name><etal/></person-group><article-title>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury</article-title><source>Nat. Med.</source><year>2005</year><volume>11</volume><fpage>875</fpage><lpage>879</lpage><pub-id pub-id-type="pmid">16007097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1267</pub-id><pub-id pub-id-type="pmcid">PMC7095783</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains</article-title><source>Cell Host Microbe</source><year>2020</year><volume>28</volume><fpage>867</fpage><lpage>879 e865</lpage><pub-id pub-id-type="pmid">33271067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2020.11.004</pub-id><pub-id pub-id-type="pmcid">PMC7670890</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>T</given-names></name><etal/></person-group><article-title>A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent</article-title><source>Nat. Struct. Mol. Biol.</source><year>2021</year><volume>28</volume><fpage>202</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">33432247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41594-020-00549-3</pub-id><pub-id pub-id-type="pmcid">PMC7895301</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>W</given-names></name><name name-style="western"><surname>Gui</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y</given-names></name></person-group><article-title>Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2</article-title><source>PLoS Pathog.</source><year>2018</year><volume>14</volume><fpage>e1007236</fpage><pub-id pub-id-type="pmid">30102747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1007236</pub-id><pub-id pub-id-type="pmcid">PMC6107290</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>429</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">32526206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.05.042</pub-id><pub-id pub-id-type="pmcid">PMC7250779</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sungnak</surname><given-names>W</given-names></name><etal/></person-group><article-title>SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>681</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">32327758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0868-6</pub-id><pub-id pub-id-type="pmcid">PMC8637938</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells</article-title><source>Int. J. Med. Sci.</source><year>2020</year><volume>17</volume><fpage>1522</fpage><lpage>1531</lpage><pub-id pub-id-type="pmid">32669955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijms.46695</pub-id><pub-id pub-id-type="pmcid">PMC7359402</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>X</given-names></name><etal/></person-group><article-title>Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection</article-title><source>Front. Med.</source><year>2020</year><volume>14</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">32170560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11684-020-0754-0</pub-id><pub-id pub-id-type="pmcid">PMC7088738</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahn</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Nasal ciliated cells are primary targets for SARS-CoV-2 replication in early stage of COVID-19</article-title><source>J. Clin. Invest.</source><year>2021</year><pub-id pub-id-type="doi">10.1172/JCI148517</pub-id><pub-id pub-id-type="pmid">34003804</pub-id><pub-id pub-id-type="pmcid">PMC8245175</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>IT</given-names></name><etal/></person-group><article-title>ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs</article-title><source>Nat. Commun.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41467-020-19145-6</pub-id><pub-id pub-id-type="pmid">33116139</pub-id><pub-id pub-id-type="pmcid">PMC7595232</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice - a renoprotective combination?</article-title><source>Hypertension</source><year>2004</year><volume>43</volume><fpage>1120</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">15078862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.HYP.0000126192.27644.76</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindner</surname><given-names>D</given-names></name><etal/></person-group><article-title>Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases</article-title><source>JAMA Cardiol.</source><year>2020</year><volume>5</volume><fpage>1281</fpage><lpage>1285</lpage><pub-id pub-id-type="pmid">32730555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamacardio.2020.3551</pub-id><pub-id pub-id-type="pmcid">PMC7385672</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>M-W</given-names></name><etal/></person-group><article-title>Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>2693</fpage><lpage>2701</lpage><pub-id pub-id-type="pmid">32497323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.26139</pub-id><pub-id pub-id-type="pmcid">PMC7300907</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract</article-title><source>Dev. Cell</source><year>2020</year><volume>53</volume><fpage>514</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">32425701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.devcel.2020.05.012</pub-id><pub-id pub-id-type="pmcid">PMC7229915</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziegler</surname><given-names>CGK</given-names></name><etal/></person-group><article-title>SARS-CoV-2 receptor ACE2 Is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>1016</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">32413319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.04.035</pub-id><pub-id pub-id-type="pmcid">PMC7252096</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onabajo</surname><given-names>OO</given-names></name><etal/></person-group><article-title>Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor</article-title><source>Nat. Genet.</source><year>2020</year><volume>52</volume><fpage>1283</fpage><lpage>1293</lpage><pub-id pub-id-type="pmid">33077916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-020-00731-9</pub-id><pub-id pub-id-type="pmcid">PMC9377523</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>SA</given-names></name><name name-style="western"><surname>Kwok</surname><given-names>S</given-names></name><name name-style="western"><surname>Berry</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Montine</surname><given-names>TJ</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 (ACE2) expression increases with age in patients requiring mechanical ventilation</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><fpage>e0247060</fpage><pub-id pub-id-type="pmid">33592054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0247060</pub-id><pub-id pub-id-type="pmcid">PMC7886150</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muus</surname><given-names>C</given-names></name><etal/></person-group><article-title>Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>546</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">33654293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-01227-z</pub-id><pub-id pub-id-type="pmcid">PMC9469728</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation</article-title><source>Aging Cell</source><year>2020</year><pub-id pub-id-type="doi">10.1111/acel.13168</pub-id><pub-id pub-id-type="pmid">32558150</pub-id><pub-id pub-id-type="pmcid">PMC7323071</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patanavanich</surname><given-names>R</given-names></name><name name-style="western"><surname>Glantz</surname><given-names>SA</given-names></name></person-group><article-title>Smoking is associated with COVID-19 progression: a meta-analysis</article-title><source>Nicotine Tob. Res.</source><year>2020</year><volume>22</volume><fpage>1653</fpage><lpage>1656</lpage><pub-id pub-id-type="pmid">32399563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ntr/ntaa082</pub-id><pub-id pub-id-type="pmcid">PMC7239135</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>1915</fpage><lpage>1921</lpage><pub-id pub-id-type="pmid">32293753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.25889</pub-id><pub-id pub-id-type="pmcid">PMC7262275</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobs</surname><given-names>M</given-names></name><etal/></person-group><article-title>Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects</article-title><source>Eur. Respir. J.</source><year>2020</year><pub-id pub-id-type="doi">10.1183/13993003.02378-2020</pub-id><pub-id pub-id-type="pmid">32675207</pub-id><pub-id pub-id-type="pmcid">PMC7366177</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>JM</given-names></name><etal/></person-group><article-title>ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19</article-title><source>Eur. Respir. J.</source><year>2020</year><pub-id pub-id-type="doi">10.1183/13993003.00688-2020</pub-id><pub-id pub-id-type="pmid">32269089</pub-id><pub-id pub-id-type="pmcid">PMC7144263</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossato</surname><given-names>M</given-names></name><etal/></person-group><article-title>Current smoking is not associated with COVID-19</article-title><source>Eur. Respir. J.</source><year>2020</year><pub-id pub-id-type="doi">10.1183/13993003.01290-2020</pub-id><pub-id pub-id-type="pmid">32350106</pub-id><pub-id pub-id-type="pmcid">PMC7191113</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Factors associated with COVID-19-related death using OpenSAFELY</article-title><source>Nature</source><year>2020</year><volume>584</volume><fpage>430</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">32640463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2521-4</pub-id><pub-id pub-id-type="pmcid">PMC7611074</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>MC</given-names></name><etal/></person-group><article-title>COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2020</year><volume>202</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">32348692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.202003-0821OC</pub-id><pub-id pub-id-type="pmcid">PMC7328313</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furuhashi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker</article-title><source>Am. J. Hypertens.</source><year>2015</year><volume>28</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">24842388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajh/hpu086</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>L</given-names></name><name name-style="western"><surname>Karakiulakis</surname><given-names>G</given-names></name><name name-style="western"><surname>Roth</surname><given-names>M</given-names></name></person-group><article-title>Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?</article-title><source>Lancet Respir. Med.</source><year>2020</year><volume>8</volume><fpage>e21</fpage><pub-id pub-id-type="pmid">32171062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(20)30116-8</pub-id><pub-id pub-id-type="pmcid">PMC7118626</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>AB</given-names></name><name name-style="western"><surname>Verma</surname><given-names>A</given-names></name></person-group><article-title>COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1769</fpage><lpage>1770</lpage><pub-id pub-id-type="pmid">32208485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.4812</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mancia</surname><given-names>G</given-names></name><name name-style="western"><surname>Rea</surname><given-names>F</given-names></name><name name-style="western"><surname>Ludergnani</surname><given-names>M</given-names></name><name name-style="western"><surname>Apolone</surname><given-names>G</given-names></name><name name-style="western"><surname>Corrao</surname><given-names>G</given-names></name></person-group><article-title>Renin-angiotensin-aldosterone system blockers and the risk of Covid-19</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>2431</fpage><lpage>2440</lpage><pub-id pub-id-type="pmid">32356627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2006923</pub-id><pub-id pub-id-type="pmcid">PMC7206933</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>HR</given-names></name><etal/></person-group><article-title>Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>2441</fpage><lpage>2448</lpage><pub-id pub-id-type="pmid">32356628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2008975</pub-id><pub-id pub-id-type="pmcid">PMC7206932</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mou</surname><given-names>H</given-names></name><etal/></person-group><article-title>Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2</article-title><source>PLoS Pathog.</source><year>2021</year><volume>17</volume><fpage>e1009501</fpage><pub-id pub-id-type="pmid">33836016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1009501</pub-id><pub-id pub-id-type="pmcid">PMC8059821</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China</article-title><source>Science</source><year>2003</year><volume>302</volume><fpage>276</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">12958366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1087139</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>TT</given-names></name><etal/></person-group><article-title>Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins</article-title><source>Nature</source><year>2020</year><volume>583</volume><fpage>282</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">32218527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2169-0</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?</article-title><source>PLoS Pathog.</source><year>2020</year><volume>16</volume><fpage>e1008421</fpage><pub-id pub-id-type="pmid">32407364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1008421</pub-id><pub-id pub-id-type="pmcid">PMC7224457</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>K</given-names></name><etal/></person-group><article-title>Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins</article-title><source>Nature</source><year>2020</year><volume>583</volume><fpage>286</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">32380510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2313-x</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peiris</surname><given-names>JS</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>KY</given-names></name></person-group><article-title>Severe acute respiratory syndrome</article-title><source>Nat. Med.</source><year>2004</year><volume>10</volume><fpage>S88</fpage><lpage>S97</lpage><pub-id pub-id-type="pmid">15577937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1143</pub-id><pub-id pub-id-type="pmcid">PMC7096017</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><etal/></person-group><article-title>A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1/S2 cleavage site of the spike protein</article-title><source>Curr. Biol.</source><year>2020</year><volume>30</volume><fpage>2196</fpage><lpage>2203 e2193</lpage><pub-id pub-id-type="pmid">32416074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cub.2020.05.023</pub-id><pub-id pub-id-type="pmcid">PMC7211627</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name><etal/></person-group><article-title>ACE2 receptor usage reveals variation in susceptibility to SARS-CoV and SARS-CoV-2 infection among bat species</article-title><source>Nat. Ecol. Evol.</source><year>2021</year><pub-id pub-id-type="doi">10.1038/s41559-021-01407-1</pub-id><pub-id pub-id-type="pmid">33649547</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2021</year><pub-id pub-id-type="doi">10.1073/pnas.2025373118</pub-id><pub-id pub-id-type="pmid">33658332</pub-id><pub-id pub-id-type="pmcid">PMC8000431</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeffers</surname><given-names>SA</given-names></name><etal/></person-group><article-title>CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>15748</fpage><lpage>15753</lpage><pub-id pub-id-type="pmid">15496474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0403812101</pub-id><pub-id pub-id-type="pmcid">PMC524836</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>ZY</given-names></name><etal/></person-group><article-title>pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>5642</fpage><lpage>5650</lpage><pub-id pub-id-type="pmid">15140961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.78.11.5642-5650.2004</pub-id><pub-id pub-id-type="pmcid">PMC415834</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amraie</surname><given-names>R</given-names></name><etal/></person-group><article-title>CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2</article-title><source>ACS Cent. Sci.</source><year>2021</year><pub-id pub-id-type="doi">10.1021/acscentsci.0c01537</pub-id><pub-id pub-id-type="pmcid">PMC8265543</pub-id><pub-id pub-id-type="pmid">34341769</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khoo</surname><given-names>US</given-names></name><name name-style="western"><surname>Chan</surname><given-names>KY</given-names></name><name name-style="western"><surname>Chan</surname><given-names>VS</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CL</given-names></name></person-group><article-title>DC-SIGN and L-SIGN: the SIGNs for infection</article-title><source>J. Mol. Med.</source><year>2008</year><volume>86</volume><fpage>861</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">18458800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00109-008-0350-2</pub-id><pub-id pub-id-type="pmcid">PMC7079906</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geijtenbeek</surname><given-names>TB</given-names></name><etal/></person-group><article-title>Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses</article-title><source>Cell</source><year>2000</year><volume>100</volume><fpage>575</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">10721994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0092-8674(00)80693-5</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ichimura</surname><given-names>T</given-names></name><etal/></person-group><article-title>KIM-1/TIM-1 is a receptor for SARS-CoV-2 in lung and kidney</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.09.16.20190694</pub-id><pub-id pub-id-type="pmid">32995803</pub-id><pub-id pub-id-type="pmcid">PMC7523142</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells</article-title><source>Cell Res.</source><year>2021</year><volume>31</volume><fpage>126</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">33420426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-020-00460-y</pub-id><pub-id pub-id-type="pmcid">PMC7791157</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amara</surname><given-names>A</given-names></name><name name-style="western"><surname>Mercer</surname><given-names>J</given-names></name></person-group><article-title>Viral apoptotic mimicry</article-title><source>Nat. Rev. Microbiol.</source><year>2015</year><volume>13</volume><fpage>461</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">26052667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro3469</pub-id><pub-id pub-id-type="pmcid">PMC7097103</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jemielity</surname><given-names>S</given-names></name><etal/></person-group><article-title>TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><fpage>e1003232</fpage><pub-id pub-id-type="pmid">23555248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1003232</pub-id><pub-id pub-id-type="pmcid">PMC3610696</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richard</surname><given-names>AS</given-names></name><etal/></person-group><article-title>AXL-dependent infection of human fetal endothelial cells distinguishes Zika virus from other pathogenic flaviviruses</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>2024</fpage><lpage>2029</lpage><pub-id pub-id-type="pmid">28167751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1620558114</pub-id><pub-id pub-id-type="pmcid">PMC5338370</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marzi</surname><given-names>A</given-names></name><etal/></person-group><article-title>DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>12090</fpage><lpage>12095</lpage><pub-id pub-id-type="pmid">15479853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.78.21.12090-12095.2004</pub-id><pub-id pub-id-type="pmcid">PMC523257</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Function of HAb18G/CD147 in invasion of host cells by severe acute respiratory syndrome coronavirus</article-title><source>J. Infect. Dis.</source><year>2005</year><volume>191</volume><fpage>755</fpage><lpage>760</lpage><pub-id pub-id-type="pmid">15688292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/427811</pub-id><pub-id pub-id-type="pmcid">PMC7110046</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group><article-title>CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells</article-title><source>Signal. Transduct. Target. Ther.</source><year>2020</year><volume>5</volume><fpage>283</fpage><pub-id pub-id-type="pmid">33277466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-00426-x</pub-id><pub-id pub-id-type="pmcid">PMC7714896</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>LB</given-names></name><etal/></person-group><article-title>Insights on SARS-CoV-2 molecular interactions with the renin-angiotensin system</article-title><source>Front. Cell Dev. Biol.</source><year>2020</year><volume>8</volume><fpage>559841</fpage><pub-id pub-id-type="pmid">33042994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2020.559841</pub-id><pub-id pub-id-type="pmcid">PMC7525006</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shilts</surname><given-names>J</given-names></name><name name-style="western"><surname>Crozier</surname><given-names>TWM</given-names></name><name name-style="western"><surname>Greenwood</surname><given-names>EJD</given-names></name><name name-style="western"><surname>Lehner</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Wright</surname><given-names>GJ</given-names></name></person-group><article-title>No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>413</fpage><pub-id pub-id-type="pmid">33432067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-80464-1</pub-id><pub-id pub-id-type="pmcid">PMC7801465</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cantuti-Castelvetri</surname><given-names>L</given-names></name><etal/></person-group><article-title>Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>856</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">33082293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd2985</pub-id><pub-id pub-id-type="pmcid">PMC7857391</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daly</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Neuropilin-1 is a host factor for SARS-CoV-2 infection</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>861</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">33082294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd3072</pub-id><pub-id pub-id-type="pmcid">PMC7612957</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhen-Lu</surname><given-names>L</given-names></name><name name-style="western"><surname>Matthias</surname><given-names>B</given-names></name></person-group><article-title>Neuropilin-1 assists SARS-CoV-2 infection by stimulating the separation of spike protein domains S1 and S2</article-title><source>Biophys. J.</source><year>2021</year><pub-id pub-id-type="doi">10.1016/j.bpj.2021.05.026</pub-id><pub-id pub-id-type="pmcid">PMC8169233</pub-id><pub-id pub-id-type="pmid">34087218</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camargo</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations</article-title><source>Gastroenterology</source><year>2009</year><volume>136</volume><fpage>872</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">19185582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2008.10.055</pub-id><pub-id pub-id-type="pmcid">PMC7094282</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belouzard</surname><given-names>S</given-names></name><name name-style="western"><surname>Chu</surname><given-names>VC</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><article-title>Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>5871</fpage><lpage>5876</lpage><pub-id pub-id-type="pmid">19321428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0809524106</pub-id><pub-id pub-id-type="pmcid">PMC2660061</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>6013</fpage><pub-id pub-id-type="pmid">33243994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-19808-4</pub-id><pub-id pub-id-type="pmcid">PMC7693302</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peacock</surname><given-names>TP</given-names></name><etal/></person-group><article-title>The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets</article-title><source>Nat. Microbiol.</source><year>2021</year><volume>6</volume><fpage>899</fpage><lpage>909</lpage><pub-id pub-id-type="pmid">33907312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-021-00908-w</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Limburg</surname><given-names>H</given-names></name><etal/></person-group><article-title>TMPRSS2 is the major activating protease of influenza a virus in primary human airway cells and influenza B virus in human type II pneumocytes</article-title><source>J. Virol.</source><year>2019</year><pub-id pub-id-type="doi">10.1128/JVI.00649-19</pub-id><pub-id pub-id-type="pmid">31391268</pub-id><pub-id pub-id-type="pmcid">PMC6803253</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>LW</given-names></name><name name-style="western"><surname>Mao</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>YL</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections</article-title><source>Biochimie</source><year>2017</year><volume>142</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">28778717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biochi.2017.07.016</pub-id><pub-id pub-id-type="pmcid">PMC7116903</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakai</surname><given-names>K</given-names></name><etal/></person-group><article-title>TMPRSS2 independency for haemagglutinin cleavage in vivo differentiates influenza B virus from influenza A virus</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>29430</fpage><pub-id pub-id-type="pmid">27389476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep29430</pub-id><pub-id pub-id-type="pmcid">PMC4937385</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szabo</surname><given-names>R</given-names></name><name name-style="western"><surname>Bugge</surname><given-names>TH</given-names></name></person-group><article-title>Type II transmembrane serine proteases in development and disease</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2008</year><volume>40</volume><fpage>1297</fpage><lpage>1316</lpage><pub-id pub-id-type="pmid">18191610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biocel.2007.11.013</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szabo</surname><given-names>R</given-names></name><name name-style="western"><surname>Bugge</surname><given-names>TH</given-names></name></person-group><article-title>Membrane-anchored serine proteases in vertebrate cell and developmental biology</article-title><source>Annu. Rev. Cell Dev. Biol.</source><year>2011</year><volume>27</volume><fpage>213</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">21721945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-cellbio-092910-154247</pub-id><pub-id pub-id-type="pmcid">PMC3391589</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>F</given-names></name><name name-style="western"><surname>Qian</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2020</year><volume>526</volume><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">32199615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2020.03.044</pub-id><pub-id pub-id-type="pmcid">PMC7156119</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2020</year><volume>202</volume><fpage>756</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">32663409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.202001-0179LE</pub-id><pub-id pub-id-type="pmcid">PMC7462411</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lukassen</surname><given-names>S</given-names></name><etal/></person-group><article-title>SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells</article-title><source>EMBO J.</source><year>2020</year><volume>39</volume><fpage>e105114</fpage><pub-id pub-id-type="pmid">32246845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.20105114</pub-id><pub-id pub-id-type="pmcid">PMC7232010</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laporte</surname><given-names>M</given-names></name><name name-style="western"><surname>Naesens</surname><given-names>L</given-names></name></person-group><article-title>Airway proteases: an emerging drug target for influenza and other respiratory virus infections</article-title><source>Curr. Opin. Virol.</source><year>2017</year><volume>24</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">28414992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coviro.2017.03.018</pub-id><pub-id pub-id-type="pmcid">PMC7102789</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>T</given-names></name><etal/></person-group><article-title>Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2</article-title><source>PLoS Pathog.</source><year>2021</year><volume>17</volume><fpage>e1009212</fpage><pub-id pub-id-type="pmid">33465165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1009212</pub-id><pub-id pub-id-type="pmcid">PMC7845965</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozono</surname><given-names>S</given-names></name><etal/></person-group><article-title>SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>848</fpage><pub-id pub-id-type="pmid">33558493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-21118-2</pub-id><pub-id pub-id-type="pmcid">PMC7870668</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>961</fpage><pub-id pub-id-type="pmid">33574281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-21213-4</pub-id><pub-id pub-id-type="pmcid">PMC7878750</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">32142651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosch</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Bartelink</surname><given-names>W</given-names></name><name name-style="western"><surname>Rottier</surname><given-names>PJ</given-names></name></person-group><article-title>Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>8887</fpage><lpage>8890</lpage><pub-id pub-id-type="pmid">18562523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00415-08</pub-id><pub-id pub-id-type="pmcid">PMC2519682</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebert</surname><given-names>DH</given-names></name><name name-style="western"><surname>Deussing</surname><given-names>J</given-names></name><name name-style="western"><surname>Peters</surname><given-names>C</given-names></name><name name-style="western"><surname>Dermody</surname><given-names>TS</given-names></name></person-group><article-title>Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>24609</fpage><lpage>24617</lpage><pub-id pub-id-type="pmid">11986312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M201107200</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandran</surname><given-names>K</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Felbor</surname><given-names>U</given-names></name><name name-style="western"><surname>Whelan</surname><given-names>SP</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>JM</given-names></name></person-group><article-title>Endosomal proteolysis of the ebola virus glycoprotein is necessary for infection</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>1643</fpage><pub-id pub-id-type="pmid">15831716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1110656</pub-id><pub-id pub-id-type="pmcid">PMC4797943</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaik</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Structural basis of coreceptor recognition by HIV-1 envelope spike</article-title><source>Nature</source><year>2019</year><volume>565</volume><fpage>318</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">30542158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-018-0804-9</pub-id><pub-id pub-id-type="pmcid">PMC6391877</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>GR</given-names></name><name name-style="western"><surname>To</surname><given-names>RK</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>J</given-names></name><name name-style="western"><surname>Spector</surname><given-names>SA</given-names></name></person-group><article-title>SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway</article-title><source>iScience</source><year>2021</year><volume>24</volume><fpage>102295</fpage><pub-id pub-id-type="pmid">33718825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2021.102295</pub-id><pub-id pub-id-type="pmcid">PMC7939994</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jangra</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sterilizing immunity against SARS-CoV-2 infection in mice by a single-shot and lipid amphiphile imidazoquinoline TLR7/8 agonist-adjuvanted recombinant spike protein vaccine</article-title><source>Angew Chem. Int. Ed.</source><year>2021</year><volume>60</volume><fpage>9467</fpage><lpage>9473</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202015362</pub-id><pub-id pub-id-type="pmcid">PMC8014308</pub-id><pub-id pub-id-type="pmid">33464672</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Opposing activities of IFITM proteins in SARS-CoV-2 infection</article-title><source>EMBO J.</source><year>2021</year><volume>40</volume><fpage>e106501</fpage><pub-id pub-id-type="pmid">33270927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.2020106501</pub-id><pub-id pub-id-type="pmcid">PMC7744865</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winstone</surname><given-names>H</given-names></name><etal/></person-group><article-title>The polybasic cleavage site in SARS-CoV-2 spike modulates viral sensitivity to type I interferon and IFITM2</article-title><source>J. Virol.</source><year>2021</year><pub-id pub-id-type="doi">10.1128/JVI.02422-20</pub-id><pub-id pub-id-type="pmid">33563656</pub-id><pub-id pub-id-type="pmcid">PMC8104117</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfaender</surname><given-names>S</given-names></name><etal/></person-group><article-title>LY6E impairs coronavirus fusion and confers immune control of viral disease</article-title><source>Nat. Microbiol.</source><year>2020</year><volume>5</volume><fpage>1330</fpage><lpage>1339</lpage><pub-id pub-id-type="pmid">32704094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-020-0769-y</pub-id><pub-id pub-id-type="pmcid">PMC7916999</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><etal/></person-group><article-title>LY6E restricts entry of human coronaviruses, including currently pandemic SARS-CoV-2</article-title><source>J. Virol.</source><year>2020</year><pub-id pub-id-type="doi">10.1128/JVI.00562-20</pub-id><pub-id pub-id-type="pmid">32641482</pub-id><pub-id pub-id-type="pmcid">PMC7459569</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brass</surname><given-names>AL</given-names></name><etal/></person-group><article-title>The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus</article-title><source>Cell</source><year>2009</year><volume>139</volume><fpage>1243</fpage><lpage>1254</lpage><pub-id pub-id-type="pmid">20064371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2009.12.017</pub-id><pub-id pub-id-type="pmcid">PMC2824905</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>IC</given-names></name><etal/></person-group><article-title>Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus</article-title><source>PLoS Pathog.</source><year>2011</year><volume>7</volume><fpage>e1001258</fpage><pub-id pub-id-type="pmid">21253575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1001258</pub-id><pub-id pub-id-type="pmcid">PMC3017121</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>SY</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Aliyari</surname><given-names>R</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G</given-names></name></person-group><article-title>Systematic identification of type I and type II interferon-induced antiviral factors</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>4239</fpage><lpage>4244</lpage><pub-id pub-id-type="pmid">22371602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1114981109</pub-id><pub-id pub-id-type="pmcid">PMC3306696</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoggins</surname><given-names>JW</given-names></name><etal/></person-group><article-title>A diverse range of gene products are effectors of the type I interferon antiviral response</article-title><source>Nature</source><year>2011</year><volume>472</volume><fpage>481</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">21478870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature09907</pub-id><pub-id pub-id-type="pmcid">PMC3409588</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>SL</given-names></name></person-group><article-title>Interferon-inducible LY6E protein promotes HIV-1 infection</article-title><source>J. Biol. Chem.</source><year>2017</year><volume>292</volume><fpage>4674</fpage><lpage>4685</lpage><pub-id pub-id-type="pmid">28130445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M116.755819</pub-id><pub-id pub-id-type="pmcid">PMC5377782</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hackett</surname><given-names>BA</given-names></name><name name-style="western"><surname>Cherry</surname><given-names>S</given-names></name></person-group><article-title>Flavivirus internalization is regulated by a size-dependent endocytic pathway</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>4246</fpage><lpage>4251</lpage><pub-id pub-id-type="pmid">29610346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1720032115</pub-id><pub-id pub-id-type="pmcid">PMC5910848</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mar</surname><given-names>KB</given-names></name><etal/></person-group><article-title>LY6E mediates an evolutionarily conserved enhancement of virus infection by targeting a late entry step</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>3603</fpage><pub-id pub-id-type="pmid">30190477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-06000-y</pub-id><pub-id pub-id-type="pmcid">PMC6127192</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Emergence of SARS-CoV-2 through recombination and strong purifying selection</article-title><source>Sci. Adv.</source><year>2020</year><volume>6</volume><fpage>eabb9153</fpage><pub-id pub-id-type="pmid">32937441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abb9153</pub-id><pub-id pub-id-type="pmcid">PMC7458444</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boni</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic</article-title><source>Nat. Microbiol.</source><year>2020</year><volume>5</volume><fpage>1408</fpage><lpage>1417</lpage><pub-id pub-id-type="pmid">32724171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-020-0771-4</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menachery</surname><given-names>VD</given-names></name><etal/></person-group><article-title>A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence</article-title><source>Nat. Med.</source><year>2015</year><volume>21</volume><fpage>1508</fpage><lpage>1513</lpage><pub-id pub-id-type="pmid">26552008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.3985</pub-id><pub-id pub-id-type="pmcid">PMC4797993</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>EC</given-names></name></person-group><article-title>A genomic perspective on the origin and emergence of SARS-CoV-2</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">32220310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.03.035</pub-id><pub-id pub-id-type="pmcid">PMC7194821</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>KG</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A</given-names></name><name name-style="western"><surname>Lipkin</surname><given-names>WI</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>EC</given-names></name><name name-style="western"><surname>Garry</surname><given-names>RF</given-names></name></person-group><article-title>The proximal origin of SARS-CoV-2</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>450</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">32284615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0820-9</pub-id><pub-id pub-id-type="pmcid">PMC7095063</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klimstra</surname><given-names>WB</given-names></name><etal/></person-group><article-title>SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients</article-title><source>J. Gen. Virol.</source><year>2020</year><pub-id pub-id-type="doi">10.1099/jgv.0.001481</pub-id><pub-id pub-id-type="pmid">32821033</pub-id><pub-id pub-id-type="pmcid">PMC7879561</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogando</surname><given-names>NS</given-names></name><etal/></person-group><article-title>SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology</article-title><source>J. Gen. Virol.</source><year>2020</year><volume>101</volume><fpage>925</fpage><lpage>940</lpage><pub-id pub-id-type="pmid">32568027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/jgv.0.001453</pub-id><pub-id pub-id-type="pmcid">PMC7654748</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasaki</surname><given-names>M</given-names></name><etal/></person-group><article-title>SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells</article-title><source>PLoS Pathog.</source><year>2021</year><volume>17</volume><fpage>e1009233</fpage><pub-id pub-id-type="pmid">33476327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1009233</pub-id><pub-id pub-id-type="pmcid">PMC7853460</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pohl</surname><given-names>MO</given-names></name><etal/></person-group><article-title>SARS-CoV-2 variants reveal features critical for replication in primary human cells</article-title><source>PLos Biol.</source><year>2021</year><pub-id pub-id-type="doi">10.1371/journal.pbio.3001006</pub-id><pub-id pub-id-type="pmid">33760807</pub-id><pub-id pub-id-type="pmcid">PMC8021179</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mykytyn</surname><given-names>AZ</given-names></name><etal/></person-group><article-title>SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site</article-title><source>eLife</source><year>2021</year><pub-id pub-id-type="doi">10.7554/eLife.64508</pub-id><pub-id pub-id-type="pmid">33393462</pub-id><pub-id pub-id-type="pmcid">PMC7806259</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamers</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation</article-title><source>eLife</source><year>2021</year><volume>10</volume><fpage>e66815</fpage><pub-id pub-id-type="pmid">33835028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.66815</pub-id><pub-id pub-id-type="pmcid">PMC8131099</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korber</surname><given-names>B</given-names></name><etal/></person-group><article-title>Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>812</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">32697968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.06.043</pub-id><pub-id pub-id-type="pmcid">PMC7332439</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>CB</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M</given-names></name><name name-style="western"><surname>Choe</surname><given-names>H</given-names></name></person-group><article-title>Functional importance of the D614G mutation in the SARS-CoV-2 spike protein</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2021</year><volume>538</volume><fpage>108</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">33220921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2020.11.026</pub-id><pub-id pub-id-type="pmcid">PMC7664360</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>A</given-names></name></person-group><article-title>Structural impact of mutation D614G in SARS-CoV-2 spike protein: enhanced infectivity and therapeutic opportunity</article-title><source>ACS Med. Chem. Lett.</source><year>2020</year><volume>11</volume><fpage>1667</fpage><lpage>1670</lpage><pub-id pub-id-type="pmid">32934770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsmedchemlett.0c00410</pub-id><pub-id pub-id-type="pmcid">PMC7433342</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michaud</surname><given-names>WA</given-names></name><name name-style="western"><surname>Boland</surname><given-names>GM</given-names></name><name name-style="western"><surname>Rabi</surname><given-names>SA</given-names></name></person-group><article-title>The SARS-CoV-2 spike mutation D614G increases entry fitness across a range of ACE2 levels, directly outcompetes the wild type, and is preferentially incorporated into trimers</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.08.25.267500</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juraszek</surname><given-names>J</given-names></name><etal/></person-group><article-title>Stabilizing the closed SARS-CoV-2 spike trimer</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>244</fpage><pub-id pub-id-type="pmid">33431842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-20321-x</pub-id><pub-id pub-id-type="pmcid">PMC7801441</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name><etal/></person-group><article-title>D614G spike mutation increases SARS CoV-2 susceptibility to neutralization</article-title><source>Cell Host Microbe</source><year>2021</year><volume>29</volume><fpage>23</fpage><lpage>31 e24</lpage><pub-id pub-id-type="pmid">33306985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2020.11.012</pub-id><pub-id pub-id-type="pmcid">PMC7707640</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yurkovetskiy</surname><given-names>L</given-names></name><etal/></person-group><article-title>Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.032</pub-id><pub-id pub-id-type="pmid">32991842</pub-id><pub-id pub-id-type="pmcid">PMC7492024</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benton</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2021</year><pub-id pub-id-type="doi">10.1073/pnas.2022586118</pub-id><pub-id pub-id-type="pmid">33579792</pub-id><pub-id pub-id-type="pmcid">PMC7936381</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Starr</surname><given-names>TN</given-names></name><etal/></person-group><article-title>Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>1295</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">32841599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.08.012</pub-id><pub-id pub-id-type="pmcid">PMC7418704</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>SK</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Moore</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Choe</surname><given-names>H</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M</given-names></name></person-group><article-title>A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>3197</fpage><lpage>3201</lpage><pub-id pub-id-type="pmid">14670965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.C300520200</pub-id><pub-id pub-id-type="pmcid">PMC7982343</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group><article-title>The basis of a more contagious 501Y.V1 variant of SARS-CoV-2</article-title><source>Cell Res.</source><year>2021</year><volume>31</volume><fpage>720</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">33893398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-021-00496-8</pub-id><pub-id pub-id-type="pmcid">PMC8063779</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>F</given-names></name><etal/></person-group><article-title>N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2</article-title><source>eLife</source><year>2021</year><pub-id pub-id-type="doi">10.7554/eLife.69091</pub-id><pub-id pub-id-type="pmid">34414884</pub-id><pub-id pub-id-type="pmcid">PMC8455130</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>1603</fpage><lpage>1607</lpage><pub-id pub-id-type="pmid">32732280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc4730</pub-id><pub-id pub-id-type="pmcid">PMC7574913</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kidd</surname><given-names>M</given-names></name><etal/></person-group><article-title>S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR</article-title><source>J. Infect. Dis.</source><year>2021</year><pub-id pub-id-type="doi">10.1093/infdis/jiab082</pub-id><pub-id pub-id-type="pmid">33580259</pub-id><pub-id pub-id-type="pmcid">PMC7928763</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>K</given-names></name><name name-style="western"><surname>Shum</surname><given-names>MH</given-names></name><name name-style="western"><surname>Leung</surname><given-names>GM</given-names></name><name name-style="western"><surname>Lam</surname><given-names>TT</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JT</given-names></name></person-group><article-title>Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020</article-title><source>Euro Surveill.</source><year>2021</year><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.26.1.2002106</pub-id><pub-id pub-id-type="pmid">33413740</pub-id><pub-id pub-id-type="pmcid">PMC7791602</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>W</given-names></name><etal/></person-group><article-title>Circulating SARS-CoV-2 variants B.1.1.7, 501Y.V2, and P.1 have gained ability to utilize rat and mouse Ace2 and altered in vitro sensitivity to neutralizing antibodies and ACE2-Ig</article-title><source>bioRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.01.27.428353</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montagutelli</surname><given-names>X</given-names></name><etal/></person-group><article-title>The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice</article-title><source>bioRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.03.18.436013</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adam</surname><given-names>D</given-names></name></person-group><article-title>What scientists know about new, fast-spreading coronavirus variants</article-title><source>Nature</source><year>2021</year><volume>594</volume><fpage>19</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">34031583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-021-01390-4</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frazier</surname><given-names>L</given-names></name><etal/></person-group><article-title>Spike protein cleavage-activation mediated by the SARS-CoV-2 P681R mutation: a case-study from its first appearance in variant of interest (VOI) A.23.1 identified in Uganda</article-title><source>bioRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.06.30.450632</pub-id><pub-id pub-id-type="pmid">35766497</pub-id><pub-id pub-id-type="pmcid">PMC9430374</pub-id></element-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>2384</fpage><lpage>2393</lpage><pub-id pub-id-type="pmid">33794143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.03.036</pub-id><pub-id pub-id-type="pmcid">PMC7980144</pub-id></element-citation></ref><ref id="CR190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><etal/></person-group><article-title>SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines</article-title><source>Cell Host Microbe</source><year>2021</year><pub-id pub-id-type="doi">10.1016/j.chom.2021.03.002</pub-id><pub-id pub-id-type="pmid">33705729</pub-id><pub-id pub-id-type="pmcid">PMC7934674</pub-id></element-citation></ref><ref id="CR191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greaney</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies</article-title><source>Cell Host Microbe</source><year>2021</year><volume>29</volume><fpage>463</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">33592168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2021.02.003</pub-id><pub-id pub-id-type="pmcid">PMC7869748</pub-id></element-citation></ref><ref id="CR192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><etal/></person-group><article-title>Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization</article-title><source>Cell Host Microbe</source><year>2021</year><volume>29</volume><fpage>747</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">33887205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2021.04.007</pub-id><pub-id pub-id-type="pmcid">PMC8053237</pub-id></element-citation></ref><ref id="CR193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piccoli</surname><given-names>L</given-names></name><etal/></person-group><article-title>Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>1024</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">32991844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.09.037</pub-id><pub-id pub-id-type="pmcid">PMC7494283</pub-id></element-citation></ref><ref id="CR194"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomson</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>1171</fpage><lpage>1187</lpage><pub-id pub-id-type="pmid">33621484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.01.037</pub-id><pub-id pub-id-type="pmcid">PMC7843029</pub-id></element-citation></ref><ref id="CR195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>717</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">33664494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01294-w</pub-id><pub-id pub-id-type="pmcid">PMC8058618</pub-id></element-citation></ref><ref id="CR196"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baum</surname><given-names>A</given-names></name><etal/></person-group><article-title>Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>1014</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">32540904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd0831</pub-id><pub-id pub-id-type="pmcid">PMC7299283</pub-id></element-citation></ref><ref id="CR197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Starr</surname><given-names>TN</given-names></name><etal/></person-group><article-title>Prospective mapping of viral mutations that escape antibodies used to treat COVID-19</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>850</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">33495308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abf9302</pub-id><pub-id pub-id-type="pmcid">PMC7963219</pub-id></element-citation></ref><ref id="CR198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andreano</surname><given-names>E</given-names></name><etal/></person-group><article-title>SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2021</year><pub-id pub-id-type="doi">10.1073/pnas.2103154118</pub-id><pub-id pub-id-type="pmid">34417349</pub-id><pub-id pub-id-type="pmcid">PMC8433494</pub-id></element-citation></ref><ref id="CR199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>3426</fpage><lpage>3437</lpage><pub-id pub-id-type="pmid">33991487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.04.025</pub-id><pub-id pub-id-type="pmcid">PMC8057738</pub-id></element-citation></ref><ref id="CR200"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerutti</surname><given-names>G</given-names></name><etal/></person-group><article-title>Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite</article-title><source>Cell Host Microbe</source><year>2021</year><pub-id pub-id-type="doi">10.1016/j.chom.2021.03.005</pub-id><pub-id pub-id-type="pmid">33789084</pub-id><pub-id pub-id-type="pmcid">PMC7953435</pub-id></element-citation></ref><ref id="CR201"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lok</surname><given-names>SM</given-names></name></person-group><article-title>An NTD supersite of attack</article-title><source>Cell Host Microbe</source><year>2021</year><volume>29</volume><fpage>744</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">33984277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2021.04.010</pub-id><pub-id pub-id-type="pmcid">PMC8114578</pub-id></element-citation></ref><ref id="CR202"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCallum</surname><given-names>M</given-names></name><etal/></person-group><article-title>N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>2332</fpage><lpage>2347</lpage><pub-id pub-id-type="pmid">33761326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.03.028</pub-id><pub-id pub-id-type="pmcid">PMC7962585</pub-id></element-citation></ref><ref id="CR203"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suryadevara</surname><given-names>N</given-names></name><etal/></person-group><article-title>Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>2316</fpage><lpage>2331</lpage><pub-id pub-id-type="pmid">33773105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.03.029</pub-id><pub-id pub-id-type="pmcid">PMC7962591</pub-id></element-citation></ref><ref id="CR204"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group><article-title>The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>1284</fpage><lpage>1294</lpage><pub-id pub-id-type="pmid">32730807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.07.012</pub-id><pub-id pub-id-type="pmcid">PMC7366990</pub-id></element-citation></ref><ref id="CR205"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weisblum</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants</article-title><source>eLife</source><year>2020</year><pub-id pub-id-type="doi">10.7554/eLife.61312</pub-id><pub-id pub-id-type="pmid">33112236</pub-id><pub-id pub-id-type="pmcid">PMC7723407</pub-id></element-citation></ref><ref id="CR206"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>RL</given-names></name><name name-style="western"><surname>Baric</surname><given-names>RS</given-names></name></person-group><article-title>Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>3134</fpage><lpage>3146</lpage><pub-id pub-id-type="pmid">19906932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01394-09</pub-id><pub-id pub-id-type="pmcid">PMC2838128</pub-id></element-citation></ref><ref id="CR207"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frampton</surname><given-names>D</given-names></name><etal/></person-group><article-title>Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study</article-title><source>Lancet Infect. Dis.</source><year>2021</year><pub-id pub-id-type="doi">10.1016/s1473-3099(21)00170-5</pub-id><pub-id pub-id-type="pmid">33857406</pub-id><pub-id pub-id-type="pmcid">PMC8041359</pub-id></element-citation></ref><ref id="CR208"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>NG</given-names></name><etal/></person-group><article-title>Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England</article-title><source>Science</source><year>2021</year><volume>372</volume><fpage>eabg3055</fpage><pub-id pub-id-type="pmid">33658326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abg3055</pub-id><pub-id pub-id-type="pmcid">PMC8128288</pub-id></element-citation></ref><ref id="CR209"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cele</surname><given-names>S</given-names></name><etal/></person-group><article-title>Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma</article-title><source>Nature</source><year>2021</year><volume>593</volume><fpage>142</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">33780970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03471-w</pub-id><pub-id pub-id-type="pmcid">PMC9867906</pub-id></element-citation></ref><ref id="CR210"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351</article-title><source>N. Engl. J. Med.</source><year>2021</year><pub-id pub-id-type="doi">10.1056/NEJMc2103740</pub-id><pub-id pub-id-type="pmid">33826819</pub-id><pub-id pub-id-type="pmcid">PMC8063884</pub-id></element-citation></ref><ref id="CR211"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faria</surname><given-names>NR</given-names></name><etal/></person-group><article-title>Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil</article-title><source>Science</source><year>2021</year><volume>372</volume><fpage>815</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">33853970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abh2644</pub-id><pub-id pub-id-type="pmcid">PMC8139423</pub-id></element-citation></ref><ref id="CR212"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vignier</surname><given-names>N</given-names></name><etal/></person-group><article-title>Breakthrough Infections of SARS-CoV-2 Gamma variant in fully vaccinated gold miners, French Guiana, 2021</article-title><source>Emerg. Infect. Dis.</source><year>2021</year><pub-id pub-id-type="doi">10.3201/eid2710.211427</pub-id><pub-id pub-id-type="pmid">34289335</pub-id><pub-id pub-id-type="pmcid">PMC8462339</pub-id></element-citation></ref><ref id="CR213"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farinholt</surname><given-names>T</given-names></name><etal/></person-group><article-title>Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections</article-title><source>medRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.06.28.21258780</pub-id><pub-id pub-id-type="pmid">34593004</pub-id><pub-id pub-id-type="pmcid">PMC8483940</pub-id></element-citation></ref><ref id="CR214"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Starr</surname><given-names>TN</given-names></name><name name-style="western"><surname>Greaney</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Dingens</surname><given-names>AS</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>JD</given-names></name></person-group><article-title>Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016</article-title><source>Cell Rep. Med.</source><year>2021</year><volume>2</volume><fpage>100255</fpage><pub-id pub-id-type="pmid">33842902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2021.100255</pub-id><pub-id pub-id-type="pmcid">PMC8020059</pub-id></element-citation></ref><ref id="CR215"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><etal/></person-group><article-title>B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies</article-title><source>bioRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.03.24.436620</pub-id><pub-id pub-id-type="pmid">34311587</pub-id><pub-id pub-id-type="pmcid">PMC8406170</pub-id></element-citation></ref><ref id="CR216"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>I</given-names></name><etal/></person-group><article-title>SARS-CoV-2 B.1.617 mutations L452 and E484Q are not synergistic for antibody evasion</article-title><source>J. Infect. Dis.</source><year>2021</year><pub-id pub-id-type="doi">10.1093/infdis/jiab368</pub-id><pub-id pub-id-type="pmid">34260717</pub-id><pub-id pub-id-type="pmcid">PMC8420622</pub-id></element-citation></ref><ref id="CR217"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palacios</surname><given-names>R</given-names></name><etal/></person-group><article-title>Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac - PROFISCOV: a structured summary of a study protocol for a randomised controlled trial</article-title><source>Trials</source><year>2020</year><volume>21</volume><fpage>853</fpage><pub-id pub-id-type="pmid">33059771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13063-020-04775-4</pub-id><pub-id pub-id-type="pmcid">PMC7558252</pub-id></element-citation></ref><ref id="CR218"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>FP</given-names></name><etal/></person-group><article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="CR219"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>DY</given-names></name><etal/></person-group><article-title>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>671</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">33545094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00234-8</pub-id><pub-id pub-id-type="pmcid">PMC7852454</pub-id></element-citation></ref><ref id="CR220"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></element-citation></ref><ref id="CR221"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrett</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">33335322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-01179-4</pub-id></element-citation></ref><ref id="CR222"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial</article-title><source>Lancet Infect. Dis.</source><year>2021</year><pub-id pub-id-type="doi">10.1016/s1473-3099(20)30942-7</pub-id><pub-id pub-id-type="pmid">33485468</pub-id><pub-id pub-id-type="pmcid">PMC7825810</pub-id></element-citation></ref><ref id="CR223"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercado</surname><given-names>NB</given-names></name><etal/></person-group><article-title>Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>583</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">32731257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2607-z</pub-id><pub-id pub-id-type="pmcid">PMC7581548</pub-id></element-citation></ref><ref id="CR224"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C</given-names></name><etal/></person-group><article-title>Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2320</fpage><lpage>2332</lpage><pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></element-citation></ref><ref id="CR225"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gosert</surname><given-names>R</given-names></name><name name-style="western"><surname>Kanjanahaluethai</surname><given-names>A</given-names></name><name name-style="western"><surname>Egger</surname><given-names>D</given-names></name><name name-style="western"><surname>Bienz</surname><given-names>K</given-names></name><name name-style="western"><surname>Baker</surname><given-names>SC</given-names></name></person-group><article-title>RNA replication of mouse hepatitis virus takes place at double-membrane vesicles</article-title><source>J. Virol.</source><year>2002</year><volume>76</volume><fpage>3697</fpage><lpage>3708</lpage><pub-id pub-id-type="pmid">11907209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.76.8.3697-3708.2002</pub-id><pub-id pub-id-type="pmcid">PMC136101</pub-id></element-citation></ref><ref id="CR226"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knoops</surname><given-names>K</given-names></name><etal/></person-group><article-title>SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum</article-title><source>PLoS Biol.</source><year>2008</year><volume>6</volume><fpage>e226</fpage><pub-id pub-id-type="pmid">18798692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pbio.0060226</pub-id><pub-id pub-id-type="pmcid">PMC2535663</pub-id></element-citation></ref><ref id="CR227"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snijder</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>A unifying structural and functional model of the coronavirus replication organelle: tracking down RNA synthesis</article-title><source>PLoS Biol.</source><year>2020</year><volume>18</volume><fpage>e3000715</fpage><pub-id pub-id-type="pmid">32511245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pbio.3000715</pub-id><pub-id pub-id-type="pmcid">PMC7302735</pub-id></element-citation></ref><ref id="CR228"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stertz</surname><given-names>S</given-names></name><etal/></person-group><article-title>The intracellular sites of early replication and budding of SARS-coronavirus</article-title><source>Virology</source><year>2007</year><volume>361</volume><fpage>304</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">17210170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2006.11.027</pub-id><pub-id pub-id-type="pmcid">PMC7103305</pub-id></element-citation></ref><ref id="CR229"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolff</surname><given-names>G</given-names></name><etal/></person-group><article-title>A molecular pore spans the double membrane of the coronavirus replication organelle</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>1395</fpage><lpage>1398</lpage><pub-id pub-id-type="pmid">32763915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd3629</pub-id><pub-id pub-id-type="pmcid">PMC7665310</pub-id></element-citation></ref><ref id="CR230"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldsmith</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Ultrastructural characterization of SARS coronavirus</article-title><source>Emerg. Infect. Dis.</source><year>2004</year><volume>10</volume><fpage>320</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">15030705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1002.030913</pub-id><pub-id pub-id-type="pmcid">PMC3322934</pub-id></element-citation></ref><ref id="CR231"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuman</surname><given-names>BW</given-names></name><etal/></person-group><article-title>A structural analysis of M protein in coronavirus assembly and morphology</article-title><source>J. Struct. Biol.</source><year>2011</year><volume>174</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">21130884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsb.2010.11.021</pub-id><pub-id pub-id-type="pmcid">PMC4486061</pub-id></element-citation></ref><ref id="CR232"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoeman</surname><given-names>D</given-names></name><name name-style="western"><surname>Fielding</surname><given-names>BC</given-names></name></person-group><article-title>Coronavirus envelope protein: current knowledge</article-title><source>Virol. J.</source><year>2019</year><volume>16</volume><fpage>69</fpage><pub-id pub-id-type="pmid">31133031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12985-019-1182-0</pub-id><pub-id pub-id-type="pmcid">PMC6537279</pub-id></element-citation></ref><ref id="CR233"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beigel</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Remdesivir for the treatment of covid-19 - final report</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>1813</fpage><lpage>1826</lpage><pub-id pub-id-type="pmid">32445440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2007764</pub-id><pub-id pub-id-type="pmcid">PMC7262788</pub-id></element-citation></ref><ref id="CR234"><label>234.</label><mixed-citation publication-type="other">US National Library of Medicine. <italic toggle="yes">ClinicalTrials.gov</italic><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04321096">https://clinicaltrials.gov/ct2/show/NCT04321096</ext-link> (2021).</mixed-citation></ref><ref id="CR235"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>PG</given-names></name><name name-style="western"><surname>Tang</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hua</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>An</surname><given-names>J</given-names></name></person-group><article-title>Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation</article-title><source>Cell Discov.</source><year>2020</year><volume>6</volume><fpage>71</fpage><pub-id pub-id-type="pmid">33083006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41421-020-00217-2</pub-id><pub-id pub-id-type="pmcid">PMC7550610</pub-id></element-citation></ref><ref id="CR236"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro</article-title><source>Cell Discov.</source><year>2020</year><volume>6</volume><fpage>80</fpage><pub-id pub-id-type="pmid">33298900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41421-020-00222-5</pub-id><pub-id pub-id-type="pmcid">PMC7610239</pub-id></element-citation></ref><ref id="CR237"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration</article-title><source>eLife</source><year>2020</year><pub-id pub-id-type="doi">10.7554/eLife.61552</pub-id><pub-id pub-id-type="pmid">33103998</pub-id><pub-id pub-id-type="pmcid">PMC7685702</pub-id></element-citation></ref><ref id="CR238"><label>238.</label><mixed-citation publication-type="other">Zhu, Y., Yu, D., Yan, H., Chong, H. &amp; He, Y. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity. <italic toggle="yes">J. Virol.</italic> 94, 10.1128/JVI.00635-20 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00635-20</pub-id><pub-id pub-id-type="pmcid">PMC7343218</pub-id><pub-id pub-id-type="pmid">32376627</pub-id></mixed-citation></ref><ref id="CR239"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Inhibitors of SARS-CoV-2 entry: current and future opportunities</article-title><source>J. Med. Chem.</source><year>2020</year><volume>63</volume><fpage>12256</fpage><lpage>12274</lpage><pub-id pub-id-type="pmid">32539378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.0c00502</pub-id><pub-id pub-id-type="pmcid">PMC7315836</pub-id></element-citation></ref><ref id="CR240"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salazar</surname><given-names>E</given-names></name><etal/></person-group><article-title>Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality</article-title><source>Am. J. Pathol.</source><year>2020</year><volume>190</volume><fpage>2290</fpage><lpage>2303</lpage><pub-id pub-id-type="pmid">32795424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajpath.2020.08.001</pub-id><pub-id pub-id-type="pmcid">PMC7417901</pub-id></element-citation></ref><ref id="CR241"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Libster</surname><given-names>R</given-names></name><etal/></person-group><article-title>Early high-titer plasma therapy to prevent severe Covid-19 in older adults</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>610</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">33406353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2033700</pub-id><pub-id pub-id-type="pmcid">PMC7793608</pub-id></element-citation></ref><ref id="CR242"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial</article-title><source>JAMA</source><year>2020</year><volume>324</volume><fpage>460</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">32492084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.10044</pub-id><pub-id pub-id-type="pmcid">PMC7270883</pub-id></element-citation></ref><ref id="CR243"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>STH</given-names></name><etal/></person-group><article-title>Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>1708</fpage><lpage>1713</lpage><pub-id pub-id-type="pmid">32934372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-1088-9</pub-id></element-citation></ref><ref id="CR244"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simonovich</surname><given-names>VA</given-names></name><etal/></person-group><article-title>A randomized trial of convalescent plasma in Covid-19 severe pneumonia</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>619</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">33232588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2031304</pub-id><pub-id pub-id-type="pmcid">PMC7722692</pub-id></element-citation></ref><ref id="CR245"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joyner</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Convalescent plasma antibody levels and the risk of death from Covid-19</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>1015</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">33523609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2031893</pub-id><pub-id pub-id-type="pmcid">PMC7821984</pub-id></element-citation></ref><ref id="CR246"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>A human monoclonal antibody blocking SARS-CoV-2 infection</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>2251</fpage><pub-id pub-id-type="pmid">32366817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-16256-y</pub-id><pub-id pub-id-type="pmcid">PMC7198537</pub-id></element-citation></ref><ref id="CR247"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>1505</fpage><lpage>1509</lpage><pub-id pub-id-type="pmid">32703908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc5881</pub-id><pub-id pub-id-type="pmcid">PMC7402622</pub-id></element-citation></ref><ref id="CR248"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koenig</surname><given-names>P-A</given-names></name><etal/></person-group><article-title>Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>eabe6230</fpage><pub-id pub-id-type="pmid">33436526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abe6230</pub-id><pub-id pub-id-type="pmcid">PMC7932109</pub-id></element-citation></ref><ref id="CR249"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoof</surname><given-names>M</given-names></name><etal/></person-group><article-title>An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive spike</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>1473</fpage><lpage>1479</lpage><pub-id pub-id-type="pmid">33154106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abe3255</pub-id><pub-id pub-id-type="pmcid">PMC7857409</pub-id></element-citation></ref><ref id="CR250"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahase</surname><given-names>E</given-names></name></person-group><article-title>Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients</article-title><source>BMJ</source><year>2020</year><volume>371</volume><fpage>m4362</fpage><pub-id pub-id-type="pmid">33177042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.m4362</pub-id></element-citation></ref><ref id="CR251"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial</article-title><source>JAMA</source><year>2021</year><volume>325</volume><fpage>632</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">33475701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.0202</pub-id><pub-id pub-id-type="pmcid">PMC7821080</pub-id></element-citation></ref><ref id="CR252"><label>252.</label><mixed-citation publication-type="other">Bhimraj, A. et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 (Infectious Diseases Society of America, 2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa478</pub-id><pub-id pub-id-type="pmcid">PMC7197612</pub-id><pub-id pub-id-type="pmid">32338708</pub-id></mixed-citation></ref><ref id="CR253"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>ACE2-targeting monoclonal antibody as a &#8220;pan&#8221; coronavirus blocker in vitro and in a mouse model</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.11.11.375972</pub-id></element-citation></ref><ref id="CR254"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tada</surname><given-names>T</given-names></name><etal/></person-group><article-title>An ACE2 microbody containing a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2</article-title><source>Cell Rep.</source><year>2020</year><volume>33</volume><fpage>108528</fpage><pub-id pub-id-type="pmid">33326798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2020.108528</pub-id><pub-id pub-id-type="pmcid">PMC7705358</pub-id></element-citation></ref><ref id="CR255"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monteil</surname><given-names>V</given-names></name><etal/></person-group><article-title>Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>905</fpage><lpage>913</lpage><pub-id pub-id-type="pmid">32333836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.04.004</pub-id><pub-id pub-id-type="pmcid">PMC7181998</pub-id></element-citation></ref><ref id="CR256"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sims</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Intranasal gene therapy to prevent infection by SARS-CoV-2 variants</article-title><source>PLoS Pathog.</source><year>2021</year><volume>17</volume><fpage>e1009544</fpage><pub-id pub-id-type="pmid">34265018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1009544</pub-id><pub-id pub-id-type="pmcid">PMC8282039</pub-id></element-citation></ref><ref id="CR257"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrari</surname><given-names>M</given-names></name><etal/></person-group><article-title>Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV-2 variants</article-title><source>J. Virol.</source><year>2021</year><pub-id pub-id-type="doi">10.1128/JVI.00685-21</pub-id><pub-id pub-id-type="pmid">34287040</pub-id><pub-id pub-id-type="pmcid">PMC8432736</pub-id></element-citation></ref><ref id="CR258"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haschke</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects</article-title><source>Clin. Pharmacokinet.</source><year>2013</year><volume>52</volume><fpage>783</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">23681967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-013-0072-7</pub-id></element-citation></ref><ref id="CR259"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>A</given-names></name><etal/></person-group><article-title>A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome</article-title><source>Crit. Care</source><year>2017</year><pub-id pub-id-type="doi">10.1186/s13054-017-1823-x</pub-id><pub-id pub-id-type="pmid">28877748</pub-id><pub-id pub-id-type="pmcid">PMC5588692</pub-id></element-citation></ref><ref id="CR260"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reimer</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e41451</fpage><pub-id pub-id-type="pmid">22844480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0041451</pub-id><pub-id pub-id-type="pmcid">PMC3402407</pub-id></element-citation></ref><ref id="CR261"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>NAC</given-names></name><name name-style="western"><surname>Kester</surname><given-names>KE</given-names></name><name name-style="western"><surname>Casimiro</surname><given-names>D</given-names></name><name name-style="western"><surname>Gurunathan</surname><given-names>S</given-names></name><name name-style="western"><surname>DeRosa</surname><given-names>F</given-names></name></person-group><article-title>The promise of mRNA vaccines: a biotech and industrial perspective</article-title><source>NPJ Vaccines</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41541-020-0159-8</pub-id><pub-id pub-id-type="pmid">32047656</pub-id><pub-id pub-id-type="pmcid">PMC7000814</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>